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Abstract
Human noroviruses are the primary cause of epidemic and sporadic acute gastroenteritis. The 
worldwide high morbidity and mortality associated with norovirus infections, particularly among 
the elderly, immunocompromised patients and children, constitute a serious public health concern. 
There are currently no approved human vaccines or norovirus-specific small-molecule therapeutics 
or prophylactics. Norovirus 3CL protease has recently emerged as a potential therapeutic target for 
the development of anti-norovirus agents. We hypothesized that the S4 subsite of the enzyme may 
provide an effective means of designing potent and cell permeable inhibitors of the enzyme. We 
report herein the structure-guided exploration and exploitation of the S4 subsite of norovirus 3CL 
protease in the design and synthesis of effective inhibitors of the protease.
1. Introduction
Human noroviruses belong to the family Caliciviridae and are the leading cause of acute 
gastroenteritis worldwide [1–2]. They are associated with high morbidity and a heavy 
economic burden [3–5]. In developing countries the mortality rate among children <5 years 
old due to diarrheal disease caused by noroviruses is estimated to account for 71,000 deaths 
annually [6–8]. Combating norovirus infections presents a challenge because of the facile 
foodborne and waterborne transmission of noroviruses, as well as their high genetic diversity 
*Department of Chemistry, Wichita State University, Wichita, KS 67260, Tel. (316) 978 7374; Fax: (316) 978 3431, 
bill.groutas@wichita.edu. **Department of Diagnostic Medicine & Pathobiology, Kansas State University, Manhattan, KS 66506, Tel. 
(785) 532 3849; Fax: (785) 532 4039, kchang@vet.ksu.edu. 
HHS Public Access
Author manuscript
Eur J Med Chem. Author manuscript; available in PMC 2017 July 07.
Published in final edited form as:













and environmental stability [9–10]. The problem is further exacerbated by the current lack of 
diagnostics and norovirus-specific therapeutics and prophylactics, or vaccines. Thus, there is 
an urgent and unmet medical need for the discovery and development of anti-norovirus 
small-molecule therapeutics and prophylactics [11–14], as well as effective vaccines [15–
16].
Both viral and host factors can in principle serve as a launching pad for the discovery of 
anti-norovirus therapeutics [11–14,17–20]. Prominent viral targets that are particularly well-
suited as targets for anti-noroviral drug development include the viral-encoded 3CL protease 
(3CLpro) and RNA dependent RNA polymerase (RdRp) because of the essential roles they 
play in viral replication [18]. Following translation of the viral genome, the viral polyprotein 
is cleaved by 3CLpro, a cysteine protease with a prototypical catalytic triad (Cys 139, His30, 
Glu54) and a strong preference for a P1 Gln (or Glu) residue [21], to generate structural and 
nonstructural proteins [22–24] Norovirus 3CLpro has been the focus of intense 
investigations and an array of inhibitors of 3CLpro that display anti-norovirus activity have 
been reported [11–14,19], including peptidyl [25–26] and macrocyclic [27–28] transition 
state inhibitors and transition state mimics [29]. Importantly, in vivo proof of concept in a 
mouse model using a dipeptidyl transition state inhibitor of norovirus 3CLpro has also been 
demonstrated [25]. We describe herein the structure-guided exploration of the S4 subsite of 
3CLpro and the subsequent deployment of structure-activity relationship and biochemical 
studies in the design and discovery of potent and permeable inhibitors of the enzyme.
2. Results and Discussion
2.1. Inhibitor design rationale
The design and optimization of the inhibitors was informed by the utilization of available 
crystal structures and the parallel acquisition of additional high resolution X-ray crystal 
structures. Thus, inspection of previously-determined high resolution X-ray crystal 
structures of dipeptidyl inhibitors bound to norovirus 3CL protease (PDB accession codes 
4XBB, 4XBC and 4XBD) [25] revealed that the “cap” R group in inhibitor (I) projects 
toward the S4 subsite of the enzyme and suggested that its close proximity to a string of 
hydrophobic amino acids (Ala158, Ala160, Val168 and Ile109) can be exploited through 
appropriate cap modifications, including the use of sulfonamide functionalities. Additional 
design considerations included the use of key recognition elements, such as a Gln surrogate 
[30] and a cyclohexyl methyl residue at the P1 and P2 positions, respectively, capable of 
engaging in H-bonding and hydrophobic interactions. Finally, based on the recently-
demonstrated in vivo efficacy of aldehyde bisulfite adducts [31], this moiety was 
incorporated into inhibitor (I) and, for comparative purposes, the corresponding aldehyde 
inhibitors were also included.
2.2. Chemistry
The synthesis of inhibitors 6a-7m was accomplished using the reaction sequence shown in 
Scheme 1. Briefly, N-Boc-L-cyclohexyl methyl alanine was coupled to glutamine surrogate 
8 [30] to obtain 2, followed by removal of the Boc protective group to yield intermediate 3 
which was subsequently reacted with a series of sulfonyl chlorides to yield sulfonamide 
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esters 4a–m. Reduction with lithium borohydride generated the corresponding alcohols 5a–
m. Dess-Martin periodinane oxidation of 5a–m proceeded smoothly to yield aldehydes 6a–
m which were transformed to the corresponding aldehyde bisulfite adducts 7a–m. The 
synthesized sulfonamide derivatives are listed in Table 1. Carbamates 12a–c were 
synthesized according to Scheme 2 via reaction of intermediate 3 with an appropriate 
chloroformate and further elaboration to yield the corresponding aldehydes and aldehyde 
bisulfite adducts, which are listed in Table 2.
2.3. Biochemical Studies
The inhibitory activity of the synthesized compounds against NV 3CLpro and their anti-
norovirus activity in a cell-based replicon system, were evaluated as described in the 
experimental section [32]. The determined IC50, EC50 and CC50 values are listed in Tables 1 
and 2 and they are the average of at least two determinations.
Inspection of the results in Table 1 permit the following inferences to be drawn: (a) the 
potency of the aldehyde bisulfite adducts is comparable to those of the precursor aldehydes, 
an observation noted previously [25,33]. Advantages accrued through the use of aldehyde 
bisulfite adducts include higher solubility and metabolic stability, as well as low cytotoxicity 
[31]. Whether the bisulfite adducts exert their action by functioning as transition state 
mimics or latent precursors of the aldehyde functionality, or both, has not been established 
as yet and is currently under investigation; (b) a significant increase in potency (15-fold) was 
observed when the phenyl ring is moved further into the S4 pocket (Table 1, compare the 
EC50 values of compounds 7a, 7b and 7c) and an additional 4-fold gain in potency was 
realized by extending the linker further (Table 1, compound 7l). These observations are 
congruent with the results of X-ray crystallographic studies with inhibitor 7l. Crystallization 
of NV 3CLpro with inhibitor 7l yielded hexagonal and orthorhombic crystals and the 
electron density clearly shows the sulfur atom of the active site Cys139 residue bound 
covalently to the carbonyl carbon of the P1 residue of inhibitor 7l, thereby establishing the 
mechanism of action of this class of inhibitors (Figure 2). The electrostatic surface 
representation shows the aryl ring to be optimally nestled in the hydrophobic S4 pocket of 
the enzyme and engaged in hydrophobic interactions with Ile109, Val168, Ala160 and 
Ala159 (Figure 3). Inhibitor 7l is bound to the active site of the enzyme via a network of 
hydrogen bonds in the manner of an antiparallel β-sheet and includes inhibitor backbone H-
bonds with Gln110 and Ala158 which serve to position and orient the inhibitor correctly 
with respect to the catalytic residues (Figures 4 and 5). Additionally, a H-bond with His30 
serves to stabilize the tetrahedral adduct and two critical H-bonds involving the P1 Gln 
surrogate ring oxygen with His157 and Thr134 are clearly evident; (c) halogen substitutions 
in the aromatic ring were generally beneficial (Table 1, compounds 6d/7d, 6e/7e and 6g/7g); 
(d) potency also improved when a 4-biphenyl or 2-pthalimidoethane moiety was used (Table 
1, compounds 6j/7j and 6k/7k); (e) the significance of hydrophobic interactions involving R 
and the S4 subsite was further probed by using an n-octyl chain cap, resulting in inhibitors 
displaying submicromolar ED50 values (Table 1, compounds 6m/7m). The structural 
determinants accounting for the higher potency of compounds 6m/7m were identified by 
obtaining a high resolution X-ray crystal structure of the NV 3CLpro:7m complex (Figure 
6). Inhibitor 7m adopts a binding mode in the active site similar to 7l (Figure 7) which is 
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clearly evident from the superposition of the two inhibitors in the active site of the enzyme 
(Figure 8). Furthermore, inhibitor 7m engages in identical H-bond interactions as inhibitor 
7l (Figure 9), hence the comparable potencies. Importantly, the n-octyl chain encompasses 
the S4 subsite and participates in hydrophobic interactions with the string of hydrophobic 
amino acids that make up the S4 pocket (Figure 10). The importance of hydrophobic 
interactions is similarly evident in carbamate derivatives 11c/12c (Table 2); and, (f) an eight 
to ten-fold increase in potency was realized when the sulfonamide linkage was replaced by a 
carbamate moiety (Table 2, compounds 11a/12a versus compounds 6h/7h in Table 1).
3. Conclusion
Structural, synthetic, biochemical, and cell-based studies have been employed to illuminate 
the S4 subsite of NV 3CLpro and to gain insight and understanding into the significance and 
impact of hydrophobic interactions on pharmacological activity. In principle, further gains in 
potency can be realized through the use of constrained R moieties that mitigate the entropic 
penalty incurred in using long aliphatic chains. The results reported herein provide a sound 




Reagents and dry solvents were purchased from various chemical suppliers (Chem-Impex, 
Acros Organics, TCI America, Aldrich, and Bachem) and were used as obtained. Silica gel 
(230–450 mesh) used for flash chromatography was purchased from Sorbent Technologies 
(Atlanta, GA). Thin layer chromatography was performed using Analtech silica gel plates 
(Newark, DE). Visualization was accomplished using UV light and/or iodine. NMR spectra 
were recorded in CDCl3 or DMSO-d6 using a Varian XL-400 spectrometer and are reported 
relative to TMS (δH= 0.00 ppm). Chemical shifts are reported in ppm and spin multiplicities 
are represented by the following signals: s (singlet), d (doublet), dd (doublets of doublet), t 
(triplet), q (quartet) and m (multiplet). Melting points were recorded on a Mel-Temp 
apparatus and are uncorrected. High resolution mass spectrometry (HRMS) was performed 
at the University of Kansas Mass Spectrometry lab using an LCT Premier mass spectrometer 
(Waters, Milford, MA) equipped with a time of flight mass analyzer and an electrospray ion 
source or in-house using a G6230B TOF MS (Agilent Technologies, Santa Clara, CA). The 
purity of the synthesized compounds was established using HPLC and was >95%.
4.1.1. Synthesis of compound 2—To a solution of compound 1 (10 mmol) in dry DMF 
(20 mL) was added EDCI (2.40 g, 12.5 mmol, 1.25 eq), HOBt (1.92 g, 12.5 mmol, 1.25 eq) 
and the mixture was stirred for 30 minutes at room temperature. In a separate flask, a 
solution of deprotected glutamine surrogate 8 (2.23 g, 10 mmol) in DMF (15 mL) cooled to 
0–5 °C was treated with N,N-diisopropylethylamine (DIEA) (9.5 g, 40 mmol, 4 eq), stirred 
for 30 minutes, and then added to the reaction mixture containing (L) N-Boc 
cyclohexylalanine. The reaction mixture was stirred for 12 h while monitoring the reaction 
by TLC. The solvent was removed and the residue was dissolved in ethyl acetate (200 mL) 
and washed with 10% aqueous citric acid (2 × 40 mL). The ethyl acetate layer was further 
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washed with saturated NaHCO3 (40 mL), followed by saturated NaCl (50 mL). The organic 
layer was dried over anhydrous sodium sulfate, filtered and concentrated to yield a yellow-
colored oily product. Purification by flash chromatography yielded ester 2 as a white solid.
4.1.1.1. Methyl (S)-2-((S)-2-((tert-butoxycarbonyl)amino)-3-cyclohexylpropanamido)-3-
((S)-2-oxopyrrolidin-3-yl)propanoate 2: White solid (yield 77%); M.p 72–74 °C; 1H NMR 
(400 MHz, CDCl3-d): δ ppm 0.84 – 1.04 (m, 2 H), 1.11 – 1.31 (m, 4 H), 1.44 (s, 9 H), 1.60 
– 1.75 (m, 6 H), 1.78 – 1.94 (m, 3 H), 2.15 – 2.28 (m, 1 H), 2.35 – 2.48 (m, 2 H), 3.26 – 3.40 
(m, 2 H), 3.73 (s, 3 H), 4.21 – 4.34 (m, 1 H), 4.53 (ddd, J=11.13, 7.37, 3.91 Hz, 1 H), 5.03 
(d, J=7.23 Hz, 1 H), 6.34 (s, 1 H), 7.55 (d, J=5.66 Hz, 1 H). HRMS (ESI) calcd for 
C22H37N3O6: [M-]: 439.2682. Found: 439.2866.
4.1.2. Synthesis of compound 3—To a solution of compound 2 (10 mmol) in dry DCM 
(5 mL) was added 4M HCl in dioxane (10 mL) and the mixture was stirred for 2 h at room 
temperature. The solvent was removed and the residue was dried under high vacuum to yield 
the hydrochloride salt as a pale white solid.
4.1.2.1. Methyl (S)-2-((S)-2-amino-3-cyclohexylpropanamido)-3-((S)-2-oxopyrroli din-3-
yl)propanoate hydrochloride 3: Pale white solid (yield 100%); M.p 60–62 °C; 1H NMR 
(400 MHz, DMSO-d6): δ ppm 0.87 (quin, J=10.76 Hz, 2 H), 1.09 – 1.29 (m, 3 H), 1.34 – 
1.45 (m, 2 H), 1.52 – 1.60 (m, 2 H), 1.65 (d, J=8.25 Hz, 4 H), 1.80 (d, J=12.03 Hz, 1 H), 
2.01 – 2.13 (m, 1 H), 2.12 – 2.24 (m, 2 H), 2.38 – 2.48 (m, 2 H), 3.07 – 3.23 (m, 2 H), 3.58 
(s, 3 H), 3.79 (d, J=5.30 Hz, 1 H), 4.25 (br. s, 1 H), 4.36 – 4.46 (m, 1 H), 7.69 (s, 1 H), 8.33 
(s, 1 H), 9.00 (d, J=7.74 Hz, 1 H). HRMS (ESI) calcd for C17H30ClN3O4: [M-]: 375.1925. 
Found: 375.1920.
4.1.3. Synthesis of compounds 4a–m—To a solution of compound 3 (5 mmol) in dry 
DCM (20 mL) kept at 0 °C was added triethylamine (TEA) (1.3 mL,11 mmol, 2.2 eq) slowly 
with stirring. The appropriate sulfonyl chloride derivative (5.5 mmol, 1.1 eq) was added and 
reaction mixture was stirred for 12 h at 35 °C. The solvent was removed and the residue was 
dissolved in ethyl acetate (50 mL) and washed with water (2 × 25 mL). The ethyl acetate 
layer was further washed with saturated NaCl (50 mL). The organic layer was dried over 
anhydrous sodium sulfate, filtered and concentrated to yield a crude product. Purification by 
flash chromatography yielded esters 4a–m.
4.1.3.1. Methyl (S)-2-((S)-3-cyclohexyl-2-(phenylsulfonamido)propanamido)-3-((S)-2-
oxopyrrolidin-3-yl)propanoate 4a: White solid (yield 73%); M.p 45–47 °C; 1H NMR (400 
MHz, CDCl3-d): δ ppm 0.67 – 0.79 (m, 1 H), 0.82 – 0.94 (m, 1 H), 0.98 – 1.07 (m, 2 H), 
1.10 – 1.22 (m, 1 H), 1.31 – 1.41 (m, 1 H), 1.43 – 1.65 (m, 6 H), 1.73 – 1.88 (m, 2 H), 2.02 – 
2.13 (m, 2 H), 2.19 – 2.29 (m, 1 H), 2.34 (ddd, J=12.40, 8.40, 4.00 Hz, 1 H), 3.38 (dd, 
J=8.93, 4.74 Hz, 2 H), 3.70 (s, 3 H), 3.84 (td, J=9.30, 4.93 Hz, 1 H), 4.27 (ddd, J=11.23, 
6.98, 3.86 Hz, 1 H), 5.30 (s, 1 H), 5.97 (d, J=9.18 Hz, 1 H), 6.44 (s, 1 H), 7.44 – 7.50 (m, 2 
H), 7.51 – 7.57 (m, 1 H), 7.87 (d, J=7.23 Hz, 2 H). HRMS (ESI) calcd for C23H33N3O6S: 
[M+H]: 480.2168 Found: 480.2147.
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4.1.3.2. Methyl (S)-2-((S)-3-cyclohexyl-2-((phenylmethyl)sulfonamido)propan amido)-3-
((S)-2-oxopyrrolidin-3-yl)propanoate 4b: White solid (yield 77%); M.p 41–43 °C; 1H 
NMR (400 MHz, CDCl3-d): δ ppm 0.82 – 0.98 (m, 2 H), 1.07 – 1.30 (m, 3 H), 1.42 – 1.51 
(m, 2 H), 1.59 – 1.71 (m, 5 H), 1.77 (d, J=12.45 Hz, 1 H), 1.82 – 1.96 (m, 2 H), 2.17 (ddd, 
J=14.13, 11.74, 5.66 Hz, 1 H), 2.34 – 2.44 (m, 1 H), 2.45 – 2.54 (m, 1 H), 3.31 – 3.39 (m, 2 
H), 3.73 (s, 3 H), 3.94 – 4.04 (m, 1 H), 4.22 – 4.33 (m, 2 H), 4.44 – 4.53 (m, 1 H), 5.51 (d, 
J=8.98 Hz, 1 H), 6.15 (s, 1 H), 7.33 – 7.39 (m, 3 H), 7.41 – 7.47 (m, 2 H), 7.99 (d, J=6.74 
Hz, 1 H). HRMS (ESI) calcd for C24H35N3O6S: [M+H]: 494.2325 Found: 494.2302.
4.1.3.3. Methyl (S)-2-((S)-3-cyclohexyl-2-((2-phenylethyl)sulfonamido)propan amido)-3-
((S)-2-oxopyrrolidin-3-yl)propanoate 4c: White solid (yield 82%); M.p 45–47 °C; 1H 
NMR (400 MHz, CDCl3-d): δ ppm 0.84 – 1.06 (m, 2 H), 1.09 – 1.30 (m, 4 H), 1.47 – 1.59 
(m, 2 H), 1.61 – 1.74 (m, 4 H), 1.75 – 1.94 (m, 3 H), 2.13 (ddd, J=14.08, 11.96, 5.69 Hz, 1 
H), 2.19 – 2.29 (m, 1 H), 2.30 – 2.42 (m, 1 H), 3.06 – 3.16 (m, 2 H), 3.17 – 3.34 (m, 4 H), 
3.64 (s, 3 H), 4.10 (td, J=9.02, 4.86 Hz, 1 H), 4.39 – 4.48 (m, 1 H), 5.68 (d, J=9.47 Hz, 1 H), 
6.24 (s, 1 H), 7.17 – 7.25 (m, 2 H), 7.25 – 7.35 (m, 3 H), 8.15 (d, J=6.79 Hz, 1 H). HRMS 
(ESI) calcd for C25H37N3O6S: [M+H]: 508.2481 Found: 508.2460.
4.1.3.4. Methyl (S)-2-((S)-3-cyclohexyl-2-((4-fluorophenyl)sulfonamido)propan 
amido)-3-((S)-2-oxopyrrolidin-3-yl)propanoate 4d: White solid (yield 78%); M.p 63–
65 °C; 1H NMR (400 MHz, CDCl3-d): δ ppm 0.76 (d, J=10.40 Hz, 1 H), 0.85 – 0.96 (m, 1 
H), 1.08 (d, J=9.52 Hz, 2 H), 1.13 – 1.22 (m, 1 H), 1.35 – 1.55 (m, 2 H), 1.55 – 1.66 (m, 5 
H), 1.71 (br. s., 1 H), 1.79 – 1.92 (m, 2 H), 1.99 – 2.11 (m, 1 H), 2.19 – 2.28 (m, 1 H), 2.36 
(ddd, J=12.55, 8.47, 4.37 Hz, 1 H), 3.39 (dd, J=8.93, 4.64 Hz, 2 H), 3.70 (s, 3 H), 3.81 (td, 
J=9.28, 4.93 Hz, 1 H), 4.21 – 4.29 (m, 1 H), 6.00 (d, J=9.23 Hz, 1 H), 6.31 (s, 1 H), 7.15 (t, 
J=8.54 Hz, 2 H), 7.86 – 7.92 (m, 2 H), 7.95 (d, J=6.59 Hz, 1 H). HRMS (ESI) calcd for 
C23H32FN3O6S: [M+H]: 498.2074 Found: 498.2050.
4.1.3.5. Methyl (S)-2-((S)-2-((3-chlorophenyl)sulfonamido)-3-cyclohexylpropan 
amido)-3-((S)-2-oxopyrrolidin-3-yl)propanoate 4e: White solid (yield 81%); M.p 58–
59 °C; 1H NMR (400 MHz, CDCl3-d): δ ppm 0.73 – 0.82 (m, 1 H), 0.84 – 0.94 (m, 1 H), 
1.06 (t, J=8.98 Hz, 2 H), 1.13 – 1.20 (m, 1 H), 1.40 (d, J=16.50 Hz, 1 H), 1.44 – 1.50 (m, 1 
H), 1.51 – 1.65 (m, 4 H), 1.72 (br. s., 2 H), 1.79 – 1.89 (m, 2 H), 1.97 – 2.08 (m, 1 H), 2.23 – 
2.30 (m, 1 H), 2.35 (d, J=11.52 Hz, 1 H), 3.35 – 3.42 (m, 2 H), 3.68 (s, 3 H), 3.85 (d, J=4.20 
Hz, 1 H), 4.15 – 4.23 (m, 1 H), 5.98 (d, J=9.08 Hz, 1 H), 6.27 (s, 1 H), 7.40 – 7.45 (m, 1 H), 
7.47 – 7.53 (m, 1 H), 7.75 (d, J=7.62 Hz, 1 H), 7.83 (s, 1 H), 8.16 (d, J=5.96 Hz, 1 H). 
HRMS (ESI) calcd for C23H32ClN3O6S: [M+H]: 514.1779 Found: 514.1738.
4.1.3.6. Methyl (S)-2-((S)-2-((4-chlorophenyl)sulfonamido)-3-cyclohexylpropan 
amido)-3-((S)-2-oxopyrrolidin-3-yl)propanoate 4f: White solid (yield 76%); M.p 52–
54 °C; 1H NMR (400 MHz, CDCl3-d): δ ppm 0.70 – 0.83 (m, 1 H), 0.89 (q, J=11.00 Hz, 1 
H), 1.03 – 1.12 (m, 1 H), 1.13 – 1.22 (m, 1 H), 1.37 – 1.54 (m, 2 H), 1.57 – 1.68 (m, 5 H), 
1.71 (br. s., 1 H), 1.80 – 1.91 (m, 2 H), 1.97 – 2.09 (m, 2 H), 2.17 – 2.26 (m, 1 H), 2.32 – 
2.45 (m, 1 H), 3.36 – 3.46 (m, 2 H), 3.70 (s, 3 H), 3.80 (td, J=9.25, 4.98 Hz, 1 H), 4.16 – 
4.25 (m, 1 H), 6.00 (d, J=9.28 Hz, 1 H), 6.30 (s, 1 H), 7.44 (d, J=8.59 Hz, 2 H), 7.81 (d, 
Galasiti Kankanamalage et al. Page 6













J=8.59 Hz, 2 H), 8.04 (d, J=6.35 Hz, 1 H). HRMS (ESI) calcd for C23H32ClN3O6S: [M+H]: 
514.1779 Found: 514.1770.
4.1.3.7. Methyl (S)-2-((S)-2-(((4-chlorophenyl)methyl)sulfonamido)-3-cyclohexyl 
propanamido)-3-((S)-2-oxopyrrolidin-3-yl)propanoate 4g: White solid (yield 71%); M.p 
38–39 °C; 1H NMR (400 MHz, CDCl3-d): δ ppm 0.83 – 0.98 (m, 2 H), 1.08 – 1.29 (m, 3 H), 
1.40 – 1.52 (m, 2 H), 1.60 – 1.71 (m, 5 H), 1.77 (d, J=12.30 Hz, 1 H), 1.84 – 1.98 (m, 2 H), 
2.09 – 2.20 (m, 1 H), 2.34 – 2.45 (m, 1 H), 2.46 – 2.53 (m, 1 H), 3.37 (dd, J=8.81, 4.66 Hz, 2 
H), 3.73 (s, 3 H), 3.95 – 4.03 (m, 1 H), 4.18 – 4.31 (m, 2 H), 4.40 – 4.48 (m, 1 H), 5.67 (d, 
J=8.93 Hz, 1 H), 6.21 (s, 1 H), 7.32 – 7.35 (m, 2 H), 7.38 – 7.42 (m, 2 H), 8.10 (d, J=6.49 
Hz, 1 H). HRMS (ESI) calcd for C24H34ClN3O6S: [M+H]: 528.1835 Found: 528.1879.
4.1.3.8. Methyl (S)-2-((S)-2-((2-(3-chlorophenyl)ethyl)sulfonamido)-3-cyclohexyl 
propanamido)-3-((S)-2-oxopyrrolidin-3-yl)propanoate 4h: White solid (yield 71%); M.p 
63–65 °C; 1H NMR (400 MHz, CDCl3-d): δ ppm 0.85 – 1.05 (m, 2 H), 1.12 – 1.31 (m, 3 H), 
1.49 – 1.58 (m, 2 H), 1.62 – 1.75 (m, 6 H), 1.79 – 1.96 (m, 2 H), 2.13 (ddd, J=14.10, 12.00, 
5.79 Hz, 1 H), 2.25 – 2.34 (m, 1 H), 2.36 – 2.45 (m, 1 H), 3.03 – 3.16 (m, 2 H), 3.21 – 3.29 
(m, 2 H), 3.30 – 3.39 (m, 2 H), 3.68 (s, 3 H), 4.05 – 4.16 (m, 1 H), 4.39 – 4.47 (m, 1 H), 5.80 
(d, J=9.52 Hz, 1 H), 6.28 (s, 1 H), 7.10 (d, J=6.83 Hz, 1 H), 7.19 – 7.26 (m, 3 H), 8.24 (d, 
J=6.69 Hz, 1 H). HRMS (ESI) calcd for C25H36ClN3O6S: [M+H]: 542.2092 Found: 
542.2033.
4.1.3.9. Methyl (S)-2-((S)-3-cyclohexyl-2-(thiophene-2-sulfonamido)propanamido)-3-
((S)-2-oxopyrrolidin-3-yl)propanoate 4i: White solid (yield 62%); M.p 45–47 °C; 1H 
NMR (400 MHz, CDCl3-d): δ ppm 0.72 – 0.85 (m, 1 H), 0.86 – 0.95 (m, 1 H), 1.04 – 1.15 
(m, 2 H), 1.16 – 1.27 (m, 1 H), 1.35 – 1.46 (m, 1 H), 1.50 (dd, J=9.45, 4.76 Hz, 1 H), 1.54 – 
1.67 (m, 5 H), 1.79 – 1.92 (m, 3 H), 2.04 – 2.18 (m, 1 H), 2.28 – 2.42 (m, 2 H), 3.35 – 3.41 
(m, 2 H), 3.71 (s, 3 H), 3.95 (td, J=9.19, 4.91 Hz, 1 H), 4.34 (ddd, J=11.28, 7.08, 3.81 Hz, 1 
H), 6.17 (d, J=8.93 Hz, 1 H), 6.53 (br. s., 1 H), 7.04 (dd, J=4.83, 3.91 Hz, 1 H), 7.56 (dd, 
J=4.96, 1.00 Hz, 1 H), 7.61 (dd, J=3.64, 1.05 Hz, 1 H), 7.89 (d, J=6.88 Hz, 1 H). HRMS 
(ESI) calcd for C21H31N3O6S2: [M+H]: 486.1733 Found: 486.1785.
4.1.3.10. Methyl (S)-2-((S)-2-([1,1′-biphenyl]-4-sulfonamido)-3-cyclohexylpropan 
amido)-3-((S)-2-oxopyrrolidin-3-yl)propanoate 4j: White solid (yield 62%); M.p 89–
92 °C; 1H NMR (400 MHz, CDCl3-d): δ ppm 0.73 (d, J=10.50 Hz, 1 H), 0.81 – 0.93 (m, 1 
H), 0.98 – 1.07 (m, 2 H), 1.09 – 1.18 (m, 1 H), 1.31 – 1.43 (m, 1 H), 1.45 – 1.64 (m, 6 H), 
1.67 – 1.84 (m, 3 H), 1.96 – 2.05 (m, 1 H), 2.08 – 2.19 (m, 2 H), 3.01 – 3.10 (m, 1 H), 3.17 – 
3.25 (m, 1 H), 3.66 (s, 3 H), 3.81 (td, J=9.21, 4.86 Hz, 1 H), 4.16 – 4.24 (m, 1 H), 5.92 (d, 
J=9.13 Hz, 1 H), 6.18 (s, 1 H), 7.37 – 7.42 (m, 1 H), 7.43 – 7.48 (m, 2 H), 7.57 (d, J=7.32 
Hz, 2 H), 7.66 (d, J=8.40 Hz, 2 H), 7.91 (d, J=8.40 Hz, 2 H), 8.00 (d, J=6.49 Hz, 1 H). 
HRMS (ESI) calcd for C29H37N3O6S: [M+H]: 556.2481 Found: 556.2430.
4.1.3.11. methyl (S)-2-((S)-3-cyclohexyl-2-((2-(1,3-dioxoisoindolin-2-yl)ethyl)sulfon 
amido)propanamido)-3-((S)-2-oxopyrrolidin-3-yl)propanoate 4k: White solid (yield 
72%); M.p 59–60 °C; 1H NMR (400 MHz, CDCl3-d): δ ppm 0.85 – 1.03 (m, 2 H), 1.09 – 
1.24 (m, 3 H), 1.58 (td, J=9.35, 5.74 Hz, 2 H), 1.63 – 1.77 (m, 5 H), 1.79 – 1.87 (m, 2 H), 
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1.94 (ddd, J=14.26, 7.49, 3.69 Hz, 1 H), 2.20 (ddd, J=14.04, 11.80, 5.77 Hz, 1 H), 2.35 – 
2.45 (m, 1 H), 2.48 – 2.58 (m, 1 H), 3.30 – 3.47 (m, 4 H), 3.67 (s, 3 H), 4.03 – 4.19 (m, 2 H), 
4.32 (dt, J=14.40, 7.03 Hz, 1 H), 4.43 – 4.54 (m, 1 H), 5.91 (d, J=9.11 Hz, 1 H), 6.37 (s, 1 
H), 7.67 – 7.76 (m, 2 H), 7.81 – 7.89 (m, 2 H), 8.23 (d, J=6.71 Hz, 1 H). HRMS (ESI) calcd 
for C27H36N4O8S: [M+H]: 577.2332 Found: 577.2340.
4.1.3.12. Methyl (S)-2-((S)-3-cyclohexyl-2-((3-(4-methoxyphenoxy)propyl)sulfon 
amido)propanamido)-3-((S)-2-oxopyrrolidin-3-yl)propanoate 4l: White solid (yield 
67%); M.p 49–51 °C; 1H NMR (400 MHz, CDCl3-d): δ ppm 0.86 – 1.02 (m, 2 H), 1.10 – 
1.30 (m, 3 H), 1.47 – 1.59 (m, 2 H), 1.62 – 1.74 (m, 5 H), 1.79 – 1.90 (m, 2 H), 1.93 (dt, 
J=7.03, 3.56 Hz, 1 H), 2.13 (ddd, J=14.13, 11.79, 5.96 Hz, 1 H), 2.26 (dd, J=6.13, 3.25 Hz, 2 
H), 2.31 – 2.39 (m, 1 H), 2.42 – 2.52 (m, 1 H), 3.17 – 3.26 (m, 2 H), 3.26 – 3.36 (m, 2 H), 
3.70 (s, 3 H), 3.76 (s, 3 H), 4.00 (t, J=5.86 Hz, 2 H), 4.05 – 4.15 (m, 1 H), 4.39 – 4.50 (m, 1 
H), 5.63 (d, J=9.42 Hz, 1 H), 6.16 (s, 1 H), 6.81 (s, 4 H), 8.23 (d, J=6.59 Hz, 1 H). HRMS 
(ESI) calcd for C27H41N3O8S: [M+H]: 568.2693 Found: 568.2633.
4.1.3.13. Methyl (S)-2-((S)-3-cyclohexyl-2-(octylsulfonamido)propanamido)-3-((S)-2-
oxopyrrolidin-3-yl)propanoate 4m: White solid (yield 75%); M.p 56–58 °C; 1H NMR 
(400 MHz, CDCl3-d): δ ppm 0.88 (t, J=6.79 Hz, 4 H) 0.91 – 1.04 (m, 2 H), 1.09 – 1.34 (m, 9 
H), 1.36 – 1.44 (m, 1 H), 1.46 – 1.56 (m, 1 H), 1.58 – 1.65 (m, 6 H), 1.69 (d, J=14.06 Hz, 4 
H), 1.77 – 1.89 (m, 2 H), 1.90 – 1.99 (m, 1 H), 2.09 – 2.21 (m, 1 H), 2.38 – 2.54 (m, 2 H), 
3.00 (t, J=7.96 Hz, 2 H), 3.35 – 3.43 (m, 2 H), 3.73 (s, 3 H), 3.99 – 4.09 (m, 1 H), 4.42 – 
4.50 (m, 1 H), 5.34 (d, J=9.32 Hz, 1 H), 6.04 (s, 1 H), 8.13 (d, J=6.54 Hz, 1 H). HRMS 
(ESI) calcd for C25H46N3O6S: [M+H]: 516.3107 Found: 516.3112.
4.1.4. Synthesis of alcohols 5a–m—To a solution of ester 4 (5 mmol) in anhydrous 
THF (30 mL) was added dropwise lithium borohydride (2M in THF, 7.5 mL, 15 mmol), 
followed by absolute ethyl alcohol (15 mL), and the reaction mixture was stirred at room 
temperature overnight. The reaction mixture was then acidified using 5% HCl and the pH 
was adjusted to ~2. Removal of the solvent left a residue which was taken up in ethyl acetate 
(100 mL) and the organic layer was washed with brine (25 mL), dried over anhydrous 
sodium sulfate, filtered, and concentrated to yield compounds 5a–m.
4.1.4.1. (S)-3-cyclohexyl-N-((S)-1-hydroxy-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-2-
(phenylsulfonamido)propanamide 5a: White solid (yield 95%); M.p 48–51 °C; 1H NMR 
(400 MHz, CDCl3-d): δ ppm 0.59 – 0.73 (m, 2 H), 0.76 – 0.94 (m, 2 H), 0.96 – 1.18 (m, 3 
H), 1.31 (br. s, 1 H), 1.39 – 1.64 (m, 6 H), 1.75 – 1.87 (m, 1 H), 1.96 – 2.04 (m, 2 H), 2.30 – 
2.44 (m, 2 H), 3.32 – 3.40 (m, 2 H), 3.42 – 3.49 (m, 1 H), 3.57 (dd, J=11.25, 3.25 Hz, 1 H), 
3.69 – 3.78 (m, 1 H), 3.84 – 3.93 (m, 1 H), 6.28 (d, J=8.10 Hz, 1 H), 6.37 (s, 1 H), 7.48 – 
7.53 (m, 2 H), 7.55 – 7.60 (m, 1 H), 7.71 (d, J=7.32 Hz, 1 H), 7.89 (d, J=7.47 Hz, 2 H). 
HRMS (ESI) calcd for C22H33N3O5S: [M+H]: 452.2219 Found: 452.2210.
4.1.4.2. (S)-3-cyclohexyl-N-((S)-1-hydroxy-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-2-
((phenylmethyl)sulfonamido)propanamide 5b: White solid (yield 94%); M.p 45–
47 °C; 1H NMR (400 MHz, CDCl3-d): δ ppm 0.81 – 0.96 (m, 2 H), 1.07 – 1.23 (m, 4 H), 
1.37 (br. s., 1 H), 1.43 – 1.52 (m, 1 H), 1.56 (dd, J=13.72, 6.74 Hz, 2 H), 1.62 – 1.76 (m, 6 
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H), 1.77 – 1.86 (m, 1 H), 2.38 (td, J=5.93, 3.47 Hz, 1 H), 2.46 (d, J=6.40 Hz, 1 H), 3.31 (d, 
J=7.62 Hz, 2 H), 3.54 – 3.60 (m, 1 H), 3.65 (d, J=8.49 Hz, 1 H), 3.83 – 3.93 (m, 1 H), 3.97 – 
4.06 (m, 1 H), 4.26 (s, 2 H), 5.85 (d, J=7.08 Hz, 1 H), 6.26 (s, 1 H), 7.32 – 7.38 (m, 3 H), 
7.38 – 7.43 (m, 2 H), 7.66 (d, J=7.18 Hz, 1 H). HRMS (ESI) calcd for C23H35N3O5S: [M
+H]: 466.2376 Found: 466.2360.
4.1.4.3. (S)-3-cyclohexyl-N-((S)-1-hydroxy-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-2-
((2-phenylethyl)sulfonamido)propanamide 5c: White solid (yield 94%); M.p 49–
50 °C; 1H NMR (400 MHz, CDCl3-d): δ ppm 0.84 – 1.01 (m, 2 H), 1.10 – 1.23 (m, 4 H), 
1.55 (d, J=7.23 Hz, 2 H), 1.60 – 1.74 (m, 6 H), 1.77 – 1.87 (m, 2 H), 2.20 – 2.30 (m, 1 H), 
2.33 – 2.42 (m, 1 H), 3.05 – 3.15 (m, 2 H), 3.18 – 3.33 (m, 2 H), 3.59 (d, J=18.50 Hz, 2 H), 
3.83 (br. s., 1 H), 4.01 (d, J=4.39 Hz, 2 H), 4.14 – 4.22 (m, 2 H), 6.11 (d, J=5.42 Hz, 1 H), 
6.45 (s, 1 H), 7.16 – 7.23 (m, 2 H), 7.23 – 7.33 (m, 3 H), 7.79 (d, J=6.59 Hz, 1 H). HRMS 
(ESI) calcd for C24H37N3O5S: [M+H]: 480.2532 Found: 480.2508.
4.1.4.4. (S)-3-cyclohexyl-2-((4-fluorophenyl)sulfonamido)-N-((S)-1-hydroxy-3-((S)-2-
oxopyrrolidin-3-yl)propan-2-yl)propanamide 5d: White solid (yield 96%); M.p 66–
68 °C; 1H NMR (400 MHz, CDCl3-d): δ ppm 0.63 – 0.77 (m, 1 H), 0.79 – 0.90 (m, 1 H), 
0.91 – 1.18 (m, 3 H), 1.34 (d, J=11.81 Hz, 1 H), 1.42 – 1.52 (m, 2 H), 1.52 – 1.67 (m, 6 H), 
1.79 – 1.89 (m, 1 H), 2.01 (d, J=6.40 Hz, 1 H), 2.27 – 2.42 (m, 2 H), 3.33 – 3.41 (m, 2 H), 
3.46 – 3.55 (m, 2 H), 3.58 (br. s., 1 H), 3.68 – 3.78 (m, 1 H), 3.85 – 4.01 (m, 1 H), 6.33 (s, 1 
H), 7.18 (t, J=8.28 Hz, 2 H), 7.80 (d, J=7.20 Hz, 1 H), 7.91 (dd, J=8.47, 5.00 Hz, 2 H), 8.25 
(d, J=5.82 Hz, 1 H). HRMS (ESI) calcd for C22H32FN3O5S: [M+H]: 470.2125 Found: 
470.2115.
4.1.4.5. (S)-2-((3-chlorophenyl)sulfonamido)-3-cyclohexyl-N-((S)-1-hydroxy-3-((S)-2-
oxopyrrolidin-3-yl)propan-2-yl)propanamide 5e: White solid (yield 94%); M.p 61–
63 °C; 1H NMR (400 MHz, CDCl3-d): δ ppm 0.67 – 0.80 (m, 2 H), 0.86 (q, J=11.23 Hz, 1 
H), 0.94 – 1.19 (m, 3 H), 1.38 – 1.51 (m, 3 H), 1.52 – 1.67 (m, 4 H), 1.84 (t, J=8.01 Hz, 2 
H), 1.93 – 2.01 (m, 1 H), 2.32 – 2.43 (m, 2 H), 3.33 – 3.42 (m, 2 H), 3.44 – 3.50 (m, 1 H), 
3.54 – 3.60 (m, 1 H), 3.77 (dt, J=8.86, 4.60 Hz, 1 H), 3.81 – 3.88 (m, 1 H), 4.21 (br. s, 1 H), 
6.28 (s, 1 H), 7.45 (t, J=7.79 Hz, 1 H), 7.49 – 7.56 (m, 1 H), 7.78 (d, J=7.57 Hz, 1 H), 7.84 – 
7.89 (m, 1 H), 7.97 (d, J=5.57 Hz, 1 H), 8.17 (d, J=7.20 Hz, 1 H). HRMS (ESI) calcd for 
C22H32ClN3O5S: [M+H]: 486.1829 Found: 486.1809.
4.1.4.6. (S)-2-((4-chlorophenyl)sulfonamido)-3-cyclohexyl-N-((S)-1-hydroxy-3-((S)-2-
oxopyrrolidin-3-yl)propan-2-yl)propanamide 5f: White solid (yield 93%); M.p 56–
57 °C; 1H NMR (400 MHz, CDCl3-d): δ ppm 0.65 – 0.77 (m, 1 H), 0.78 – 0.93 (m, 1 H), 
0.94 – 1.19 (m, 3 H), 1.34 – 1.42 (m, 1 H), 1.43 – 1.52 (m, 2 H), 1.53 – 1.64 (m, 5 H), 1.76 – 
1.90 (m, 2 H), 1.91 – 2.02 (m, 1 H), 2.24 – 2.33 (m, 1 H), 2.38 (dd, J=8.30, 3.32 Hz, 1 H), 
3.34 – 3.44 (m, 2 H), 3.45 – 3.52 (m, 1 H), 3.58 (d, J=8.15 Hz, 1 H), 3.82 (br. s, 1 H), 3.95 
(d, J=3.91 Hz, 1 H), 4.17 – 4.25 (m, 1 H), 5.97 (d, J=5.20 Hz, 1 H), 6.33 (s, 1 H), 7.41 – 
7.50 (m, 2 H), 7.79 – 7.89 (m, 2 H), 8.05 (d, J=7.20 Hz, 1 H). HRMS (ESI) calcd for 
C22H32ClN3O5S: [M+H]: 486.1829 Found: 486.1811.
Galasiti Kankanamalage et al. Page 9














((S)-2-oxopyrrolidin-3-yl)propan-2-yl)propanamide 5g: White solid (yield 95%); M.p 
47–48 °C; 1H NMR (400 MHz, CDCl3-d): δ ppm 0.82 – 0.95 (m, 2 H), 1.11 – 1.21 (m, 2 H), 
1.37 (d, J=4.42 Hz, 1 H), 1.43 – 1.50 (m, 1 H), 1.53 – 1.61 (m, 3 H), 1.62 – 1.75 (m, 6 H), 
1.83 (dd, J=11.42, 9.67 Hz, 1 H), 2.00 (br. s., 1 H), 2.35 – 2.52 (m, 2 H), 3.30 – 3.36 (m, 2 
H), 3.55 – 3.61 (m, 1 H), 3.64 – 3.71 (m, 1 H), 3.84 – 3.93 (m, 1 H), 4.00 (d, J=3.56 Hz, 1 
H), 4.23 (d, J=4.96 Hz, 2 H), 5.81 (d, J=8.40 Hz, 1 H), 6.11 (s, 1 H), 7.30 – 7.33 (m, 1 H), 
7.34 – 7.36 (m, 3 H), 7.80 (d, J=7.03 Hz, 1 H). HRMS (ESI) calcd for C23H34ClN3O5S: [M
+H]: 500.1986 Found: 500.1978.
4.1.4.8. (S)-2-((2-(3-chlorophenyl)ethyl)sulfonamido)-3-cyclohexyl-N-((S)-1-hydroxy-3-
((S)-2-oxopyrrolidin-3-yl)propan-2-yl)propanamide 5h: White solid (yield 96%); M.p 
67–69 °C; 1H NMR (400 MHz, CDCl3-d): δ ppm 0.86 – 1.02 (m, 2 H), 1.09 – 1.21 (m, 2 H), 
1.45 – 1.65 (m, 4 H), 1.70 (d, J=10.25 Hz, 5 H), 1.76 – 1.86 (m, 2 H), 1.99 (d, J=5.81 Hz, 1 
H), 2.25 – 2.35 (m, 1 H), 2.35 – 2.45 (m, 1 H), 3.04 – 3.16 (m, 2 H), 3.19 – 3.28 (m, 2 H), 
3.29 – 3.37 (m, 2 H), 3.49 (br. s, 1 H), 3.54 – 3.60 (m, 1 H), 3.62 – 3.69 (m, 1 H), 3.95 – 
4.05 (m, 2 H), 5.87 (d, J=9.03 Hz, 1 H), 6.17 (s, 1 H), 7.10 (d, J=6.74 Hz, 1 H), 7.20 – 7.23 
(m, 2 H), 7.24 (br. s., 1 H), 7.94 (d, J=7.03 Hz, 1 H). HRMS (ESI) calcd for 
C24H36ClN3O5S: [M+H]: 514.2142 Found: 514.2148.
4.1.4.9. (S)-3-cyclohexyl-N-((S)-1-hydroxy-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-2-
(thiophene-2-sulfonamido)propanamide 5i: White solid (yield 96%); M.p 48–50 °C; 1H 
NMR (400 MHz, DMSO-d6): δ ppm 0.65 – 0.84 (m, 2 H), 0.95 – 1.14 (m, 3 H), 1.29 – 1.38 
(m, 4 H), 1.47 – 1.64 (m, 6 H), 1.67 – 1.78 (m, 1 H), 2.01 – 2.12 (m, 2 H), 3.04 – 3.19 (m, 2 
H), 3.21 – 3.29 (m, 2 H), 3.63 (dd, J=6.96, 4.17 Hz, 1 H), 3.77 (q, J=7.53 Hz, 1 H), 4.65 (t, 
J=5.49 Hz, 1 H), 7.09 – 7.14 (m, 1 H), 7.53 – 7.54 (m, 1 H), 7.55 (s, 1 H), 7.73 (d, J=8.64 
Hz, 1 H), 7.87 (dd, J=4.88, 1.03 Hz, 1 H), 8.08 (d, J=8.35 Hz, 1 H). HRMS (ESI) calcd for 
C20H31N3O5S2: [M+H]: 458.1783 Found: 458.1739.
4.1.4.10. (S)-2-([1,1′-biphenyl]-4-sulfonamido)-3-cyclohexyl-N-((S)-1-hydroxy-3-((S)-2-
oxopyrrolidin-3-yl)propan-2-yl)propanamide 5j: White solid (yield 92%); M.p 93–
95 °C; 1H NMR (400 MHz, DMSO-d6): δ ppm 0.61 – 0.71 (m, 1 H), 0.72 – 0.82 (m, 1 H), 
0.84 – 0.95 (m, 1 H), 0.98 – 1.12 (m, 2 H), 1.25 – 1.38 (m, 3 H), 1.40 – 1.53 (m, 4 H), 1.56 
(d, J=9.28 Hz, 2 H), 1.66 – 1.79 (m, 2 H), 2.02 – 2.12 (m, 2 H), 2.86 – 2.97 (m, 1 H), 3.00 – 
3.08 (m, 1 H), 3.09 – 3.16 (m, 1 H), 3.27 (dd, J=10.04, 4.70 Hz, 1 H), 3.56 – 3.66 (m, 1 H), 
3.70 – 3.80 (m, 1 H), 4.64 (t, J=5.00 Hz, 1 H), 6.53 (s, 1 H), 7.41 – 7.46 (m, 1 H), 7.49 (d, 
J=5.30 Hz, 1 H), 7.51 – 7.55 (m, 2 H), 7.68 – 7.75 (m, 2 H), 7.82 – 7.89 (m, 4 H), 7.95 (d, 
J=8.37 Hz, 1 H). HRMS (ESI) calcd for C28H37N3O5S: [M+H]: 528.2532 Found: 528.2568.
4.1.4.11. (S)-3-cyclohexyl-2-((2-(1,3-dioxoisoindolin-2-yl)ethyl)sulfonamido)-N-((S)-1-
hydroxy-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)propanamide 5k: White solid (yield 
94%); M.p 65–66 °C; 1H NMR (400 MHz, CDCl3-d): δ ppm 0.83 – 1.01 (m, 2 H), 1.06 – 
1.21 (m, 4 H), 1.41 – 1.74 (m, 6 H), 1.80 (d, J=11.74 Hz, 2 H), 1.95 – 2.02 (m, 2 H), 2.30 – 
2.51 (m, 2 H), 3.24 – 3.38 (m, 2 H), 3.50 – 3.59 (m, 3 H), 3.64 (d, J=4.15 Hz, 1 H), 3.84 – 
3.97 (m, 1 H), 4.03 (br. s., 1 H), 4.21 – 4.34 (m, 1 H), 4.64 (s, 2 H), 5.88 (s, 1 H), 7.33 – 7.41 
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(m, 2 H), 7.48 – 7.56 (m, 1 H), 7.59 (d, J=6.18 Hz, 1 H), 7.71 – 7.76 (m, 1 H), 8.22 (d, 
J=7.30 Hz, 1 H). HRMS (ESI) calcd for C26H36N4O7S: [M+H]: 549.2383 Found: 549.2363.
4.1.4.12. (S)-3-cyclohexyl-N-((S)-1-hydroxy-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-2-
((3-(4-methoxyphenoxy)propyl)sulfonamido)propanamide 5l: White solid (yield 94%); 
M.p 58–61 °C; 1H NMR (400 MHz, CDCl3-d): δ ppm 0.87 – 1.02 (m, 2 H), 1.10 – 1.23 (m, 
2 H), 1.42 – 1.58 (m, 3 H), 1.59 – 1.74 (m, 6 H), 1.78 – 1.87 (m, 2 H), 2.00 – 2.09 (m, 1 H), 
2.20 – 2.30 (m, 2 H), 2.36 (ddd, J=9.18, 6.18, 3.34 Hz, 1 H), 2.41 – 2.51 (m, 1 H), 3.16 – 
3.26 (m, 2 H), 3.27 – 3.33 (m, 2 H), 3.36 (d, J=6.05 Hz, 1 H), 3.54 – 3.61 (m, 1 H), 3.63 – 
3.71 (m, 1 H), 3.76 (s, 3 H), 3.94 – 4.05 (m, 4 H), 5.75 (d, J=8.84 Hz, 1 H), 6.01 (s, 1 H), 
6.78 – 6.86 (m, 4 H), 7.96 (d, J=6.98 Hz, 1 H). HRMS (ESI) calcd for C26H41N3O7S: [M
+H]: 540.2743 Found: 540.2773.
4.1.4.13. (S)-3-cyclohexyl-N-((S)-1-hydroxy-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-2-
(octylsulfonamido)propanamide 5m: White solid (yield 91%); M.p 65–66 °C; 1H NMR 
(400 MHz, CDCl3-d): δ ppm 0.88 (t, J=6.71 Hz, 3 H) 0.93 – 1.03 (m, 2 H), 1.10 – 1.21 (m, 2 
H), 1.22 – 1.33 (m, 10 H), 1.36 – 1.44 (m, 2 H), 1.44 – 1.51 (m, 1 H), 1.52 – 1.58 (m, 1 H), 
1.59 – 1.75 (m, 5 H), 1.76 – 1.90 (m, 4 H), 2.01 – 2.11 (m, 2 H), 2.37 – 2.53 (m, 2 H), 2.99 
(t, J=7.96 Hz, 2 H), 3.33 – 3.40 (m, 2 H), 3.54 – 3.61 (m, 1 H), 3.64 – 3.70 (m, 1 H), 3.93 
(td, J=9.08, 5.22 Hz, 1 H), 3.97 – 4.06 (m, 1 H), 5.66 (d, J=8.98 Hz, 1 H), 6.12 (s, 1 H), 7.82 
(d, J=7.27 Hz, 1 H). HRMS (ESI) calcd for C24H45N3O5S: [M+H]: 488.3158 Found: 
488.3143.
4.1.5. Synthesis of aldehydes 6a–m—Compound 5 (5 mmol) was dissolved in 
anhydrous dichloromethane (50 mL) under a nitrogen atmosphere and cooled to 0 °C. Dess-
Martin periodinane reagent (3.18 g, 7.5 mmol, 1.5 eq) was added to the reaction mixture 
with stirring. The ice bath was removed and the reaction mixture was stirred at room 
temperature for 3 h (monitoring by TLC indicated complete disappearance of the starting 
material). A solution of 10% aqueous sodium thiosulfate (20 mL) was added and the 
solution was stirred for 15 minutes. The aqueous layer was removed and the organic layer 
was washed with 10% aqueous sodium thiosulfate (20 mL), followed by saturated aqueous 
sodium bicarbonate (2 × 20 mL), water (2 × 20 mL) and brine (20 mL). The organic layer 
was dried over anhydrous sodium sulfate, filtered and concentrated. The yellow residue was 
purified by flash chromatography using silica gel (methylene chloride/ethyl acetate/
methanol) to yield a white solid 6a–m.
4.1.5.1. (S)-3-cyclohexyl-N-((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-2-
(phenylsulfonamido)propanamide 6a: White solid (yield 74%); M.p 69–71 °C; 1H NMR 
(400 MHz, CDCl3-d): δ ppm 0.73 (dd, J=11.52, 2.93 Hz, 1 H), 0.86 (td, J=11.91, 9.37 Hz, 1 
H), 0.93 – 1.21 (m, 3 H), 1.24 – 1.36 (m, 1 H), 1.47 (ddd, J=14.16, 9.47, 4.88 Hz, 2 H), 1.51 
– 1.66 (m, 4 H), 1.71 – 1.78 (m, 2 H), 1.81 – 1.92 (m, 2 H), 2.31 – 2.42 (m, 2 H), 3.34 – 3.43 
(m, 2 H), 3.88 (td, J=9.28, 4.88 Hz, 1 H), 4.11 (dt, J=8.89, 6.10 Hz, 1 H), 6.14 (d, J=8.59 Hz, 
1 H), 6.41 (s, 1 H), 7.45 – 7.58 (m, 3 H), 7.86 – 7.91 (m, 2 H), 8.36 (d, J=5.86 Hz, 1 H), 9.23 
(d, J=0.78 Hz, 1 H). HRMS (ESI) calcd for C22H31N3O5S: [M-]: 449.1984. Found: 
449.1981.
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((phenylmethyl)sulfonamido)propanamide 6b: White solid (yield 76%); M.p 62–
64 °C; 1H NMR (400 MHz, CDCl3-d): δ ppm 0.80 – 0.97 (m, 2 H), 1.09 – 1.30 (m, 3 H), 
1.36 – 1.55 (m, 2 H), 1.57 – 1.79 (m, 6 H), 1.81 – 1.90 (m, 1 H), 1.92 – 2.02 (m, 2 H), 2.34 – 
2.43 (m, 1 H), 2.47 – 2.57 (m, 1 H), 3.31 – 3.39 (m, 2 H), 3.98 (td, J=8.50, 6.05 Hz, 1 H), 
4.22 – 4.32 (m, 2 H), 4.33 – 4.41 (m, 1 H), 5.61 (d, J=8.59 Hz, 1 H), 6.25 (s, 1 H), 7.33 – 
7.38 (m, 3 H), 7.40 – 7.45 (m, 2 H), 8.26 (d, J=6.25 Hz, 1 H), 9.49 (s, 1 H). HRMS (ESI) 
calcd for C23H33N3O5S: [M-]: 463.2141 Found: 463.2143.
4.1.5.3. (S)-3-cyclohexyl-N-((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-2-((2-
phenylethyl)sulfonamido)propanamide 6c: White solid (yield 74%); M.p 60–62 °C; 1H 
NMR (400 MHz, CDCl3-d): δ ppm 0.84 – 1.04 (m, 2 H), 1.09 – 1.30 (m, 2 H), 1.43 – 1.61 
(m, 2 H), 1.62 – 1.76 (m, 6 H), 1.78 – 1.89 (m, 2 H), 1.89 – 2.07 (m, 2 H), 2.20 – 2.33 (m, 1 
H), 2.34 – 2.46 (m, 1 H), 3.02 – 3.17 (m, 2 H), 3.19 – 3.43 (m, 4 H), 4.12 (td, J=8.96, 5.42 
Hz, 1 H), 4.33 (dt, J=10.23, 5.28 Hz, 1 H), 5.72 (d, J=9.08 Hz, 1 H), 6.30 (br. s., 1 H), 7.16 – 
7.25 (m, 3 H), 7.26 – 7.34 (m, 2 H), 8.45 (d, J=5.96 Hz, 1 H), 9.48 (s, 1 H). HRMS (ESI) 
calcd for C24H35N3O5S: [M-]: 477.2297. Found: 477.2296.
4.1.5.4. (S)-3-cyclohexyl-2-((4-fluorophenyl)sulfonamido)-N-((S)-1-oxo-3-((S)-2-
oxopyrrolidin-3-yl)propan-2-yl)propanamide 6d: White solid (yield 68%); M.p 68–
70 °C; 1H NMR (400 MHz, CDCl3-d): δ ppm 0.64 – 0.91 (m, 2 H), 0.95 – 1.20 (m, 3 H), 
1.29 – 1.38 (m, 1 H), 1.42 – 1.66 (m, 6 H), 1.71 – 1.77 (m, 1 H), 1.81 – 1.92 (m, 2 H), 2.28 – 
2.47 (m, 2 H), 3.34 – 3.44 (m, 2 H), 3.79 – 3.89 (m, 1 H), 4.12 (q, J=7.08 Hz, 1 H), 6.15 (d, 
J=8.69 Hz, 1 H), 6.35 (br. s., 1 H), 7.11 – 7.23 (m, 2 H), 7.87 – 7.95 (m, 3 H), 8.44 (d, 
J=5.52 Hz, 1 H), 9.33 (s, 1 H). HRMS (ESI) calcd for C22H30N3O5FS: [M-]: 467.1890. 
Found: 467.1889.
4.1.5.5. (S)-2-((3-chlorophenyl)sulfonamido)-3-cyclohexyl-N-((S)-1-oxo-3-((S)-2-
oxopyrrolidin-3-yl)propan-2-yl)propanamide 6e: White solid (yield 76%); M.p 52–
53 °C; 1H NMR (400 MHz, CDCl3-d): δ ppm 0.70 – 0.96 (m, 3 H), 1.00 – 1.23 (m, 4 H), 
1.33 – 1.43 (m, 1 H), 1.45 – 1.71 (m, 6 H), 1.80 – 1.91 (m, 2 H), 2.33 – 2.48 (m, 2 H), 3.35 – 
3.45 (m, 2 H), 3.85 – 3.95 (m, 1 H), 3.99 – 4.09 (m, 1 H), 6.11 (d, J=8.84 Hz, 1 H), 6.27 (br. 
s., 1 H), 7.41 – 7.49 (m, 1 H), 7.49 – 7.57 (m, 1 H), 7.75 – 7.81 (m, 1 H), 7.85 – 7.90 (m, 1 
H), 8.67 (d, J=4.98 Hz, 1 H), 9.27 (s, 1 H). HRMS (ESI) calcd for C22H30N3O5ClS: [M-]: 
483.1595. Found: 483.1593.
4.1.5.6. (S)-2-((4-chlorophenyl)sulfonamido)-3-cyclohexyl-N-((S)-1-oxo-3-((S)-2-
oxopyrrolidin-3-yl)propan-2-yl)propanamide 6f: White solid (yield 76%); M.p 72–
74 °C; 1H NMR (400 MHz, CDCl3-d): δ ppm 0.69 – 0.93 (m, 2 H), 0.97 – 1.22 (m, 4 H), 
1.25 – 1.38 (m, 1 H), 1.43 – 1.72 (m, 6 H), 1.81 – 1.91 (m, 2 H), 2.02 – 2.15 (m, 1 H), 2.24 – 
2.34 (m, 1 H), 2.35 – 2.44 (m, 1 H), 3.36 – 3.47 (m, 2 H), 3.83 (td, J=9.01, 5.18 Hz, 1 H), 
4.03 – 4.15 (m, 1 H), 6.26 (d, J=8.69 Hz, 1 H), 6.38 (s, 1 H), 7.41 – 7.53 (m, 2 H), 7.82 (d, 
J=8.54 Hz, 2 H), 8.51 (d, J=5.37 Hz, 1 H), 9.33 (s, 1 H). HRMS (ESI) calcd for 
C22H30N3O5ClS: [M-]: 483.1595. Found: 483.1591.
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((S)-2-oxopyrrolidin-3-yl)propan-2-yl)propanamide 6g: White solid (yield 75%); M.p 
52–53 °C; 1H NMR (400 MHz, CDCl3-d): δ ppm 0.80 – 0.97 (m, 2 H), 1.10 – 1.31 (m, 4 H), 
1.36 – 1.54 (m, 1 H), 1.56 – 1.78 (m, 6 H), 1.80 – 1.90 (m, 1 H), 1.92 – 1.98 (m, 2 H), 2.36 – 
2.46 (m, 1 H), 2.47 – 2.57 (m, 1 H), 3.32 – 3.42 (m, 2 H), 3.92 – 4.00 (m, 1 H), 4.12 (q, 
J=7.14 Hz, 2 H), 4.28 – 4.37 (m, 1 H), 5.69 (d, J=8.59 Hz, 1 H), 6.23 (s, 1 H), 7.30 – 7.43 
(m, 4 H), 8.39 (d, J=5.66 Hz, 1 H), 9.49 (s, 1 H). HRMS (ESI) calcd for C23H33N3O5ClS: 
[M-]: 497.1751. Found: 497.1754.
4.1.5.8. (S)-2-((2-(3-chlorophenyl)ethyl)sulfonamido)-3-cyclohexyl-N-((S)-1-oxo-3-
((S)-2-oxopyrrolidin-3-yl)propan-2-yl)propanamide 6h: White solid (yield 73%); M.p 
53–55 °C; 1H NMR (400 MHz, CDCl3-d): δ ppm 0.84 – 1.03 (m, 2 H), 1.08 – 1.31 (m, 4 H), 
1.43 – 1.57 (m, 2 H), 1.60 – 1.86 (m, 6 H), 1.89 – 1.97 (m, 2 H), 2.24 – 2.36 (m, 1 H), 2.36 – 
2.48 (m, 1 H), 3.00 – 3.13 (m, 2 H), 3.16 – 3.41 (m, 4 H), 4.06 – 4.14 (m, 1 H), 4.27 – 4.36 
(m, 1 H), 5.71 (d, J=9.28 Hz, 1 H), 6.22 (s, 1 H), 7.08 (d, J=6.83 Hz, 1 H), 7.16 – 7.24 (m, 3 
H), 8.56 (d, J=5.76 Hz, 1 H), 9.47 (s, 1 H). HRMS (ESI) calcd for C24H34N3O5ClS: [M-]: 
511.1908. Found: 511.1907.
4.1.5.9. (S)-3-cyclohexyl-N-((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)-2-
(thiophene-2-sulfonamido)propanamide 6i: White solid (yield 75%); M.p 68–69 °C; 1H 
NMR (400 MHz, CDCl3-d): δ ppm 0.70 – 0.95 (m, 2 H), 1.01 – 1.25 (m, 3 H), 1.30 – 1.41 
(m, 1 H), 1.46 – 1.70 (m, 6 H), 1.74 – 2.00 (m, 4 H), 2.32 – 2.51 (m, 2 H), 3.40 (d, J=9.08 
Hz, 2 H), 3.98 (td, J=9.01, 4.64 Hz, 1 H), 4.15 – 4.25 (m, 1 H), 6.32 (d, J=8.49 Hz, 1 H), 
6.48 (br. s., 1 H), 7.03 – 7.10 (m, 1 H), 7.55 – 7.60 (m, 1 H), 7.63 (dd, J=3.52, 0.98 Hz, 1 H), 
8.35 (d, J=5.86 Hz, 1 H), 9.31 (s, 1 H). HRMS (ESI) calcd for C20H29N3O5S2: [M-]: 
455.1549. Found: 455.1546.
4.1.5.10. (S)-2-([1,1′-biphenyl]-4-sulfonamido)-3-cyclohexyl-N-((S)-1-oxo-3-((S)-2-
oxopyrrolidin-3-yl)propan-2-yl)propanamide 6j: White solid (yield 75%); M.p 56–
58 °C; 1H NMR (400 MHz, CDCl3-d): δ ppm 0.68 – 0.80 (m, 2 H), 0.84 – 0.90 (m, 1 H), 
0.91 – 0.97 (m, 1 H), 0.98 – 1.08 (m, 1 H), 1.09 – 1.20 (m, 2 H), 1.31 – 1.44 (m, 1 H), 1.45 – 
1.68 (m, 6 H), 1.72 – 1.81 (m, 1 H), 1.81 – 1.89 (m, 1 H), 1.90 – 2.00 (m, 1 H), 2.17 – 2.37 
(m, 2 H), 3.15 – 3.25 (m, 1 H), 3.27 – 3.38 (m, 1 H), 3.87 (td, J=9.00, 4.91 Hz, 1 H), 4.04 – 
4.16 (m, 1 H), 6.13 (d, J=8.45 Hz, 1 H), 6.37 (br. s., 1 H), 7.39 – 7.44 (m, 1 H), 7.45 – 7.51 
(m, 1 H), 7.58 (d, J=7.13 Hz, 2 H), 7.68 (d, J=8.35 Hz, 2 H), 7.94 (d, J=8.35 Hz, 2 H), 8.44 
(d, J=5.61 Hz, 1 H), 9.30 (s, 1 H). HRMS (ESI) calcd for C28H35N3O5S: [M-]: 525.2297. 
Found: 525.2297.
4.1.5.11. (S)-3-cyclohexyl-2-((2-(1,3-dioxoisoindolin-2-yl)ethyl)sulfonamido)-N-((S)-1-
oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)propanamide 6k: White solid (yield 73%); 
M.p 59–61 °C; 1H NMR (400 MHz, CDCl3-d): δ ppm 0.80 – 1.04 (m, 2 H), 1.09 – 1.28 (m, 
3 H), 1.43 – 1.73 (m, 6 H), 1.80 (br. s., 2 H), 1.93 – 2.02 (m, 1 H), 2.16 – 2.23 (m, 1 H), 2.31 
– 2.46 (m, 2 H), 2.48 – 2.62 (m, 1 H), 3.24 – 3.55 (m, 4 H), 3.63 – 3.76 (m, 1 H), 4.04 – 4.19 
(m, 2 H), 4.25 – 4.40 (m, 1 H), 5.81 (d, J=8.69 Hz, 1 H), 6.23 (t, J=7.64 Hz, 1 H), 7.45 – 
7.61 (m, 1 H), 7.67 – 7.79 (m, 1 H), 7.84 (dd, J=5.37, 3.03 Hz, 1 H), 7.94 (d, J=7.62 Hz, 1 
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H), 8.57 (d, J=5.86 Hz, 1 H), 9.48 (s, 1 H). HRMS (ESI) calcd for C26H34N4O7S: [M-]: 
546.2148. Found: 546.2144.
4.1.5.12. (S)-3-cyclohexyl-2-((3-(4-methoxyphenoxy)propyl)sulfonamido)-N-((S)-1-
oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)propanamide 6l: White solid (yield 73%); 
M.p 47–49 °C; 1H NMR (400 MHz, CDCl3-d): δ ppm 0.85 – 1.03 (m, 2 H), 1.06 – 1.31 (m, 
2 H), 1.44 – 1.60 (m, 2 H), 1.62 – 1.76 (m, 6 H), 1.79 – 1.88 (m, 2 H), 1.91 – 2.00 (m, 2 H), 
2.22 – 2.31 (m, 2 H), 2.31 – 2.41 (m, 1 H), 2.44 – 2.55 (m, 1 H), 3.15 – 3.28 (m, 2 H), 3.28 – 
3.39 (m, 2 H), 3.76 (s, 3 H), 3.96 – 4.03 (m, 2 H), 4.09 (td, J=9.01, 5.42 Hz, 1 H), 4.29 – 
4.37 (m, 1 H), 5.58 (d, J=9.18 Hz, 1 H), 6.11 (s, 1 H), 6.77 – 6.87 (m, 4 H), 8.53 (d, J=5.66 
Hz, 1 H), 9.49 (s, 1 H). HRMS (ESI) calcd for C26H39N3O7S: [M-]: 537.2509. Found: 
537.2508.
4.1.5.13. (S)-3-cyclohexyl-2-(octylsulfonamido)-N-((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-
yl)propan-2-yl)propanamide 6m: sticky solid (yield 74%); 1H NMR (400 MHz, CDCl3-d): 
δ ppm 0.84 – 1.03 (m, 4 H), 1.11 – 1.35 (m, 8 H), 1.38 (d, J=6.44 Hz, 2 H), 1.48 – 1.61 (m, 
3 H), 1.62 – 1.77 (m, 8 H), 1.77 – 1.89 (m, 4 H), 1.94 – 2.02 (m, 2 H), 2.38 – 2.48 (m, 1 H), 
2.48 – 2.59 (m, 1 H), 3.00 (t, J=7.96 Hz, 2 H), 3.34 – 3.43 (m, 2 H), 4.05 (td, J=9.01, 5.22 
Hz, 1 H), 4.33 – 4.41 (m, 1 H), 5.52 (d, J=9.18 Hz, 1 H), 6.21 (s, 1 H), 8.38 (d, J=5.96 Hz, 1 
H), 9.51 (s, 1 H). HRMS (ESI) calcd for C24H43N3O5S: [M-]: 485.2923. Found: 485.2922.
4.1.6. Synthesis of bisulfite adducts 7a–m—To a solution of aldehyde 6 (5 mmol) in 
dry ethyl acetate (20 mL) was added absolute ethanol (12 mL) with stirring, followed by a 
solution of sodium bisulfite (540 mg; 5 mmol) in water (5 mL). The reaction mixture was 
stirred for 3 h at 50 °C and then allowed to cool to room temperature. The precipitate was 
vacuum filtered and the solid was thoroughly washed with absolute ethanol. The filtrate was 
dried over anhydrous sodium sulfate, filtered, and concentrated to yield a yellowish oil 
which was treated with ethyl ether (2 × 50 mL) to form a white solid. The white solid was 
stirred with ethyl ether (30 mL) and ethyl acetate (15 mL) for 5 minutes. Careful removal of 
the solvent using a pipette yielded compounds 7a–m.
4.1.6.1. Sodium (2S)-2-((S)-3-cyclohexyl-2-(phenylsulfonamido)propanamido)-1-
hydroxy-3-((S)-2-oxopyrrolidin-3-yl)propane-1-sulfonate 7a: White solid (yield 68%); 
M.p 154–156 °C; 1H NMR (400 MHz, DMSO-d6): δ ppm 0.57 – 0.82 (m, 2 H), 0.91 (d, 
J=9.18 Hz, 1 H), 1.00 – 1.14 (m, 2 H), 1.16 – 1.25 (m, 1 H), 1.29 (d, J=8.40 Hz, 1 H), 1.51 
(d, J=11.33 Hz, 6 H), 1.68 – 1.87 (m, 1 H), 1.89 – 2.10 (m, 2 H), 2.95 – 3.15 (m, 2 H), 3.71 
– 3.81 (m, 2 H), 3.87 (d, J=3.91 Hz, 1 H), 4.07 (t, J=9.23 Hz, 1 H), 5.35 (d, J=5.57 Hz, 1 H), 
5.41 (d, J=5.86 Hz, 1 H), 7.45 (br. s., 1 H), 7.49 – 7.65 (m, 4 H), 7.71 – 7.93 (m, 3 H). 
HRMS (ESI) calcd for C22H32N3O8S2Na: [M-]: 553.1529. Found: 553.1531.
4.1.6.2. Sodium (2S)-2-((S)-3-cyclohexyl-2-((phenylmethyl)sulfonamido)propan 
amido)-1-hydroxy-3-((S)-2-oxopyrrolidin-3-yl)propane-1-sulfonate 7b: White solid 
(yield 76%); M.p 137–139 °C; 1H NMR (400 MHz, DMSO-d6): δ ppm 0.85 (br. s., 2 H), 
1.01 – 1.28 (m, 3 H), 1.31 – 1.48 (m, 2 H), 1.51 – 1.83 (m, 6 H), 1.86 – 2.26 (m, 4 H), 2.90 – 
3.03 (m, 1 H), 3.11 (d, J=5.86 Hz, 1 H), 3.84 – 4.03 (m, 2 H), 4.19 – 4.30 (m, 1 H), 4.33 (s, 
1 H), 5.46 (d, J=5.47 Hz, 1 H), 5.57 (d, J=6.25 Hz, 1 H), 7.35 (br. s., 5 H), 7.46 (d, J=8.20 
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Hz, 1 H), 7.51 (br. s., 1 H), 7.73 (d, J=8.98 Hz, 1 H), 7.97 (d, J=8.98 Hz, 1 H). HRMS (ESI) 
calcd for C23H34N3O8S2Na: [M-]: 567.1685. Found: 567.1682.
4.1.6.3. Sodium (2S)-2-((S)-3-cyclohexyl-2-((2-phenylethyl)sulfonamido)propan 
amido)-1-hydroxy-3-((S)-2-oxopyrrolidin-3-yl)propane-1-sulfonate 7c: White solid 
(yield 65%); M.p 74–76 °C; 1H NMR (400 MHz, DMSO-d6): δ ppm 0.78 – 0.98 (m, 2 H), 
1.04 – 1.29 (m, 4 H), 1.44 (br. s., 3 H), 1.65 (br. s., 4 H), 1.76 – 1.93 (m, 2 H), 2.00 (br. s., 1 
H), 2.16 (br. s., 1 H), 2.69 (d, J=8.40 Hz, 1 H), 2.90 (d, J=9.96 Hz, 2 H), 3.05 (br. s., 4 H), 
3.84 (br. s., 1 H), 3.96 (br. s., 1 H), 4.17 – 4.30 (m, 1 H), 7.26 (d, J=4.59 Hz, 5 H), 7.47 (br. 
s., 1 H), 7.59 – 7.64 (m, 1 H), 7.94 (br. s., 1 H), 8.64 (d, J=7.03 Hz, 1 H). HRMS (ESI) calcd 
for C24H36N3O8S2Na: [M-]: 581.1842. Found: 581.1841.
4.1.6.4. Sodium (2S)-2-((S)-3-cyclohexyl-2-((4-fluorophenyl)sulfonamido)propan 
amido)-1-hydroxy-3-((S)-2-oxopyrrolidin-3-yl)propane-1-sulfonate 7d: White solid 
(yield 78%); M.p 75–77 °C; 1H NMR (400 MHz, DMSO-d6): δ ppm 0.64 – 0.84 (m, 2 H), 
0.88 – 0.99 (m, 1 H), 1.04 – 1.13 (m, 3 H), 1.16 – 1.26 (m, 2 H), 1.28 – 1.39 (m, 2 H), 1.55 
(d, J=9.57 Hz, 4 H), 1.69 – 1.85 (m, 1 H), 1.89 – 1.96 (m, 1 H), 2.05 – 2.14 (m, 1 H), 3.00 – 
3.16 (m, 2 H), 3.54 – 3.63 (m, 1 H), 3.70 – 3.81 (m, 1 H), 3.98 – 4.08 (m, 1 H), 5.31 (dd, 
J=16.23, 5.93 Hz, 1 H), 7.32 – 7.46 (m, 2 H), 7.53 (d, J=4.74 Hz, 1 H), 7.63 – 7.70 (m, 1 H), 
7.74 (s, 1 H), 7.79 – 7.90 (m, 2 H), 7.95 (br. s., 1 H). HRMS (ESI) calcd for 
C22H31N3O8FS2Na: [M-]: 571.1434. Found: 571.1435.
4.1.6.5. Sodium (2S)-2-((S)-2-((3-chlorophenyl)sulfonamido)-3-cyclohexylpropan 
amido)-1-hydroxy-3-((S)-2-oxopyrrolidin-3-yl)propane-1-sulfonate (7e): White solid 
(yield 78%); M.p 74–75 °C; 1H NMR (400 MHz, DMSO-d6): δ ppm 0.64 – 0.84 (m, 3 H), 
0.91 (d, J=6.40 Hz, 1 H), 1.01 – 1.21 (m, 4 H), 1.28 – 1.37 (m, 1 H), 1.42 – 1.63 (m, 4 H), 
1.67 – 1.87 (m, 2 H), 1.88 – 2.14 (m, 2 H), 3.01 – 3.21 (m, 2 H), 3.75 – 3.90 (m, 1 H), 4.01 – 
4.15 (m, 1 H), 4.26 – 4.42 (m, 1 H), 5.27 (d, J=5.27 Hz, 1 H), 6.02 – 6.10 (m, 1 H), 7.44 (br. 
s., 1 H), 7.50 – 7.60 (m, 1 H), 7.61 – 7.69 (m, 1 H), 7.70 – 7.75 (m, 1 H), 7.76 – 7.83 (m, 1 
H), 8.05 – 8.17 (m, 1 H), 8.48 – 8.60 (m, 1 H). HRMS (ESI) calcd for C22H31N3O8ClS2Na: 
[M-]: 587.1139. Found: 587.1134.
4.1.6.6. Sodium (2S)-2-((S)-2-((4-chlorophenyl)sulfonamido)-3-cyclohexylpropan 
amido)-1-hydroxy-3-((S)-2-oxopyrrolidin-3-yl)propane-1-sulfonate 7f: White soild (yield 
61%); M.p 152–153 °C; 1H NMR (400 MHz, DMSO-d6): δ ppm 0.64 – 0.86 (m, 2 H), 1.01 
– 1.12 (m, 4 H), 1.15 – 1.27 (m, 1 H), 1.29 – 1.37 (m, 2 H), 1.39 – 1.62 (m, 6 H), 1.71 – 1.93 
(m, 2 H), 1.97 – 2.09 (m, 1 H), 3.01 – 3.13 (m, 2 H), 3.73 – 3.81 (m, 1 H), 3.87 (dd, J=5.53, 
2.18 Hz, 1 H), 4.00 – 4.12 (m, 1 H), 5.28 – 5.39 (m, 1 H), 7.45 (d, J=1.88 Hz, 1 H), 7.56 – 
7.65 (m, 2 H), 7.73 – 7.87 (m, 3 H), 8.03 (d, J=13.23 Hz, 1 H). HRMS (ESI) calcd for 
C22H31N3O8ClS2Na: [M-]: 587.1139. Found: 587.1137.
4.1.6.7. Sodium (2S)-2-((S)-2-(((4-chlorophenyl)methyl)sulfonamido)-3-cyclohexyl 
propanamido)-1-hydroxy-3-((S)-2-oxopyrrolidin-3-yl)propane-1-sulfonate 7g: White 
solid (yield 61%); M.p 76–78 °C; 1H NMR (400 MHz, DMSO-d6): δ ppm 0.84 (br. s., 2 H), 
1.04 – 1.24 (m, 6 H), 1.37 (d, J=8.59 Hz, 2 H), 1.65 (d, J=8.98 Hz, 6 H), 1.84 – 1.97 (m, 1 
H), 2.08 – 2.35 (m, 3 H), 2.95 (d, J=7.42 Hz, 1 H), 3.04 – 3.18 (m, 1 H), 3.57 (dd, J=13.18, 
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6.83 Hz, 1 H), 3.74 (q, J=6.77 Hz, 1 H), 3.84 – 3.99 (m, 1 H), 4.17 – 4.38 (m, 1 H), 7.41 (br. 
s., 3 H), 7.50 – 7.55 (m, 1 H), 7.65 (br. s., 1 H), 7.92 (d, J=8.69 Hz, 1 H), 8.64 (d, J=6.83 Hz, 
1 H). HRMS (ESI) calcd for C23H33N3O8ClS2Na: [M-]: 601.1295. Found: 601.1295.
4.1.6.8. Sodium (2S)-2-((S)-2-((2-(3-chlorophenyl)ethyl)sulfonamido)-3-cyclohexyl 
propanamido)-1-hydroxy-3-((S)-2-oxopyrrolidin-3-yl)propane-1-sulfonate 7h: White 
solid (yield 71%); M.p 78–80 °C; 1H NMR (400 MHz, DMSO-d6): δ ppm 0.87 (br. s., 2 H), 
1.02 – 1.23 (m, 5 H), 1.30 – 1.53 (m, 4 H), 1.54 – 1.71 (m, 4 H), 1.74 – 1.87 (m, 2 H), 1.92 – 
2.10 (m, 1 H), 2.65 – 2.79 (m, 1 H), 2.86 – 3.00 (m, 2 H), 3.02 – 3.17 (m, 2 H), 3.73 (q, 
J=7.08 Hz, 1 H), 3.85 – 4.02 (m, 2 H), 4.20 (d, J=7.57 Hz, 1 H), 4.68 – 4.78 (m, 1 H), 7.21 – 
7.37 (m, 3 H), 7.42 – 7.51 (m, 1 H), 7.55 – 7.62 (m, 1 H), 7.69 (d, J=8.79 Hz, 1 H), 7.90 – 
7.98 (m, 1 H). HRMS (ESI) calcd for C24H35N3O8ClS2Na: [M-]: 615.1452. Found: 
615.1459.
4.1.6.9. Sodium (2S)-2-((S)-3-cyclohexyl-2-(thiophene-2-sulfonamido)propan amido)-1-
hydroxy-3-((S)-2-oxopyrrolidin-3-yl)propane-1-sulfonate 7i: White solid (yield 67%); 
M.p 156–158 °C; 1H NMR (400 MHz, DMSO-d6): δ ppm 0.64 – 0.83 (m, 2 H), 0.92 – 1.13 
(m, 4 H), 1.16 – 1.25 (m, 1 H), 1.28 – 1.38 (m, 1 H), 1.55 (d, J=11.38 Hz, 6 H), 1.70 – 1.95 
(m, 2 H), 1.97 – 2.15 (m, 2 H), 2.97 – 3.19 (m, 2 H), 3.74 – 3.84 (m, 1 H), 3.84 – 3.94 (m, 1 
H), 4.05 – 4.17 (m, 1 H), 5.31 (t, J=6.93 Hz, 1 H), 7.09 (t, J=4.00 Hz, 1 H), 7.45 (s, 1 H), 
7.54 – 7.60 (m, 1 H), 7.73 (d, J=8.93 Hz, 1 H), 7.82 – 7.87 (m, 1 H), 8.05 (br. s., 1 H). 
HRMS (ESI) calcd for C20H30N3O8S3Na: [M-]: 599.1093. Found: 599.1094.
4.1.6.10. Sodium (2S)-2-((S)-2-([1,1′-biphenyl]-4-sulfonamido)-3-cyclohexylpropan 
amido)-1-hydroxy-3-((S)-2-oxopyrrolidin-3-yl)propane-1-sulfonate 7j: White solid (yield 
59%); M.p 154–156 °C; 1H NMR (400 MHz, DMSO-d6): δ ppm 0.66 (d, J=4.98 Hz, 1 H), 
0.76 (d, J=10.64 Hz, 1 H), 0.87 (br. s., 1 H), 1.00 – 1.13 (m, 4 H), 1.16 – 1.24 (m, 1 H), 1.29 
– 1.39 (m, 3 H), 1.41 – 1.62 (m, 6 H), 1.73 – 1.84 (m, 1 H), 1.89 – 2.05 (m, 1 H), 2.85 – 2.93 
(m, 1 H), 2.97 – 3.09 (m, 1 H), 3.61 (dd, J=10.20, 3.37 Hz, 1 H), 3.71 – 3.83 (m, 1 H), 3.87 
– 3.94 (m, 1 H), 5.31 (t, J=5.08 Hz, 1 H), 7.38 (d, J=3.81 Hz, 1 H), 7.42 – 7.47 (m, 2 H), 
7.51 (d, J=2.05 Hz, 2 H), 7.58 – 7.66 (m, 1 H), 7.69 – 7.78 (m, 2 H), 7.80 – 7.90 (m, 2 H), 
7.94 (d, J=7.42 Hz, 1 H). HRMS (ESI) calcd for C28H36N3O8S2Na: [M-]: 629.1842. Found: 
629.1844.
4.1.6.11 Sdium (2S)-2-((S)-3-cyclohexyl-2-((2-(1,3-dioxoisoindolin-2-yl)ethyl)sulfon 
amido)propanamido)-1-hydroxy-3-((S)-2-oxopyrrolidin-3-yl)propane-1-sulfonate 
7k: White solid (yield 76%); M.p 74–76 °C; 1H NMR (400 MHz, DMSO-d6): δ ppm 0.85 
(br. s., 2 H), 0.99 – 1.27 (m, 5 H), 1.41 (br. s., 2 H), 1.53 – 1.74 (m, 6 H), 1.80 – 1.92 (m, 1 
H), 2.05 – 2.31 (m, 2 H), 2.96 – 3.14 (m, 2 H), 3.54 – 3.65 (m, 1 H), 3.74 (q, J=7.13 Hz, 2 
H), 3.94 (d, J=6.05 Hz, 3 H), 4.31 – 4.41 (m, 1 H), 6.03 – 6.15 (m, 1 H), 6.63 (dd, J=9.03, 
2.10 Hz, 1 H), 7.43 – 7.55 (m, 2 H), 7.59 – 7.74 (m, 1 H), 7.83 – 7.94 (m, 2 H), 8.62 – 8.71 
(m, 1 H). HRMS (ESI) calcd for C26H35N4O10S2Na: [M-]: 650.1692. Found: 650.1693.
4.1.6.12. Sodium (2S)-2-((S)-3-cyclohexyl-2-((3-(4-methoxyphenoxy)propyl)sulfon 
amido)propanamido)-1-hydroxy-3-((S)-2-oxopyrrolidin-3-yl)propane-1-sulfonate 
7l: White solid (yield 63%); M.p 65–67 °C; 1H NMR (400 MHz, DMSO-d6): δ ppm 0.85 (d, 
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J=10.74 Hz, 2 H), 1.02 – 1.30 (m, 3 H), 1.33 – 1.50 (m, 2 H), 1.52 – 1.69 (m, 6 H), 1.71 – 
1.84 (m, 2 H), 1.88 – 2.22 (m, 5 H), 2.93 – 3.04 (m, 2 H), 3.05 – 3.17 (m, 2 H), 3.69 (s, 3 H), 
3.80 (br. s., 1 H), 3.85 – 3.92 (m, 1 H), 3.95 – 4.07 (m, 2 H), 4.22 (br. s., 1 H), 5.47 (d, 
J=5.86 Hz, 1 H), 6.85 (s, 4 H), 7.37 – 7.51 (m, 1 H), 7.65 (d, J=8.98 Hz, 1 H), 7.94 (d, 
J=8.89 Hz, 1 H). HRMS (ESI) calcd for C26H40N3O10S2Na: [M-]: 641.2053. Found: 
641.2051.
4.1.6.13. Sodium (2S)-2-((S)-3-cyclohexyl-2-(octylsulfonamido)propanamido)-1-
hydroxy-3-((S)-2-oxopyrrolidin-3-yl)propane-1-sulfonate 7m: White solid (yield 65%); 
M.p 58–60 °C; 1H NMR (400 MHz, DMSO-d6): δ ppm 0.82 – 0.92 (m, 4 H), 1.04 – 1.19 
(m, 2 H), 1.24 (br. s., 6 H), 1.36 – 1.50 (m, 2 H), 1.63 (d, J=11.42 Hz, 6 H), 1.77 (d, J=10.84 
Hz, 2 H), 1.86 – 2.04 (m, 2 H), 2.05 – 2.14 (m, 3 H), 2.15 – 2.25 (m, 1 H), 2.83 – 2.96 (m, 2 
H), 3.00 – 3.08 (m, 2 H), 3.14 (t, J=8.35 Hz, 2 H), 3.76 (d, J=8.30 Hz, 1 H), 3.85 (t, J=4.88 
Hz, 2 H), 3.92 – 4.06 (m, 1 H), 4.22 (t, J=9.62 Hz, 1 H), 5.41 (d, J=5.86 Hz, 1 H), 7.21 – 
7.29 (m, 1 H), 7.47 (d, J=5.47 Hz, 1 H), 7.62 (d, J=9.08 Hz, 1 H), 7.88 (d, J=8.98 Hz, 1 H). 
HRMS (ESI) calcd for C24H44N3O8S2Na: [M-]: 589.2468. Found: 589.2466.
4.1.7. Synthesis of esters 9a–c—To a solution of the hydrochloride salt of ester 3 (10 
mmol) in anhydrous THF (40 mL) kept at 0 °C was added slowly N,N-
diisopropylethylamine (DIEA) (2.6 mL,20 mmol, 2 eq) with stirring. The appropriate 
chloroformate (11 mmol, 1.1 eq) was added to the solution and the reaction mixture was 
stirred for 16 h at room temperature. The solvent was removed and the residue was dissolved 
in ethyl acetate (100 mL) and washed with water (2 × 50 mL). The ethyl acetate layer was 
further washed with 5% HCl (2 × 50 mL) and saturated NaCl (50 mL). The organic layer 
was dried over anhydrous sodium sulfate, filtered and concentrated to yield a crude product 
which was purification by flash chromatography to yield esters 9a–c.
4.1.7.1. Methyl (S)-2-((S)-2-(((3-chlorophenethoxy)carbonyl)amino)-3-
cyclohexylpropan amido)-3-((S)-2-oxopyrrolidin-3-yl)propanoate 9a: White solid (yield 
73%); M.p 43–45 °C; 1H NMR (400 MHz, CDCl3-d): δ ppm 0.84 – 1.02 (m, 2 H), 1.09 – 
1.23 (m, 3 H), 1.38 (d, J=2.64 Hz, 1 H), 1.45 – 1.53 (m, 1 H), 1.69 (d, J=10.20 Hz, 6 H), 
1.79 – 1.95 (m, 2 H), 2.12 – 2.22 (m, 1 H), 2.36 – 2.46 (m, 2 H), 2.87 – 2.94 (m, 2 H), 3.34 
(d, J=6.88 Hz, 2 H), 3.73 (s, 3 H), 4.20 – 4.35 (m, 3 H), 4.48 (ddd, J=11.12, 7.07, 3.88 Hz, 1 
H), 5.29 (d, J=8.25 Hz, 1 H), 6.18 (s, 1 H), 7.08 – 7.13 (m, 1 H), 7.19 – 7.26 (m, 3 H), 7.84 
(d, J=5.52 Hz, 1 H). HRMS (ESI) calcd for C26H37ClN3O6: [M+H]: 522.2371 Found: 
522.2372.
4.1.7.2. Methyl (8S,11S)-8-(cyclohexylmethyl)-6,9-dioxo-11-(((S)-2-oxopyrrolidin-3-
yl)methyl)-1-phenyl-2,5-dioxa-7,10-diazadodecan-12-oate9b: White solid (yield 67%); 
M.p 59–61 °C; 1H NMR (400 MHz, CDCl3-d): δ ppm 0.86 – 1.03 (m, 2 H), 1.09 – 1.29 (m, 
4 H), 1.34 – 1.44 (m, 2 H), 1.45 – 1.55 (m, 1 H), 1.60 – 1.73 (m, 5 H), 1.75 – 1.95 (m, 2 H), 
2.10 – 2.22 (m, 1 H), 2.35 – 2.46 (m, 2 H), 3.30 (d, J=8.40 Hz, 2 H), 3.67 (q, J=4.65 Hz, 2 
H), 3.72 (s, 3 H), 4.18 – 4.28 (m, 2 H), 4.32 (d, J=5.66 Hz, 1 H), 4.49 (ddd, J=11.05, 7.02, 
3.95 Hz, 1 H), 4.56 (s, 2 H), 5.40 (d, J=8.30 Hz, 1 H), 6.11 (s, 1 H), 7.28 – 7.31 (m, 1 H), 
Galasiti Kankanamalage et al. Page 17













7.34 (s, 4 H), 7.76 (d, J=6.83 Hz, 1 H). HRMS (ESI) calcd for C27H39N3O7: [M+H]: 
518.2866 Found: 518.2874.
4.1.7.3. Methyl (S)-2-((S)-3-cyclohexyl-2-undecanamidopropanamido)-3-((S)-2-oxop 
yrrolidin-3-yl)propanoate 9c: White solid (yield 60%); M.p 67–68 °C; 1H NMR (400 
MHz, CDCl3-d): δ ppm 0.88 (t, J=6.44 Hz, 4 H), 0.91 – 1.03 (m, 2 H), 1.10 – 1.21 (m, 2 H), 
1.23 – 1.36 (m, 14 H), 1.37 – 1.44 (m, 1 H), 1.45 – 1.54 (m, 1 H), 1.57 – 1.66 (m, 2 H), 1.70 
(d, J=8.59 Hz, 2 H), 1.78 – 1.98 (m, 5 H), 2.11 – 2.26 (m, 2 H), 2.37 – 2.48 (m, 2 H), 3.35 
(d, J=7.81 Hz, 2 H), 3.73 (s, 3 H), 3.98 – 4.12 (m, 2 H), 4.33 (d, J=4.78 Hz, 1 H), 4.46 – 
4.56 (m, 1 H), 5.21 (d, J=7.91 Hz, 1 H), 6.23 (s, 2 H), 7.77 (d, J=5.66 Hz, 1 H). HRMS 
(ESI) calcd for C28H49N3O6: [M+H]: 524.3700 Found: 524.3712.
4.1.8. Synthesis of alcohols 10a–c—To a solution of ester 9 (5 mmol) in anhydrous 
THF (30 mL) was added dropwise lithium borohydride (2M in THF, 7.5 mL, 15 mmol), 
followed by absolute ethyl alcohol (15 mL), and the reaction mixture was stirred at room 
temperature overnight. The reaction mixture was acidified with 5% HCl and the pH adjusted 
to ~2. Removal of the solvent left a residue which was taken up in ethyl acetate (100 mL). 
The organic layer was washed with brine (25 mL), dried over anhydrous sodium sulfate, 
filtered, and concentrated to yield compounds 10a–c.
4.1.8.1. 3-chlorophenethyl ((S)-3-cyclohexyl-1-(((S)-1-hydroxy-3-((S)-2-oxopyrrolidin-3-
yl)propan-2-yl)amino)-1-oxopropan-2-yl)carbamate 10a: White solid (yield 93%); M.p 
55–56 °C; 1H NMR (400 MHz, CDCl3-d): δ ppm 0.86 – 0.96 (m, 2 H), 1.18 (d, J=17.43 Hz, 
3 H), 1.29 – 1.37 (m, 2 H), 1.39 – 1.52 (m, 1 H), 1.66 (br. s., 6 H), 1.76 – 1.88 (m, 2 H), 2.00 
(br. s., 1 H), 2.34 – 2.49 (m, 2 H), 2.84 – 2.94 (m, 2 H), 3.33 (d, J=8.18 Hz, 2 H), 3.61 (d, 
J=15.55 Hz, 2 H), 3.94 – 4.02 (m, 1 H), 4.19 – 4.31 (m, 3 H), 5.36 (d, J=7.23 Hz, 1 H), 6.20 
(s, 1 H), 7.10 (d, J=6.47 Hz, 1 H), 7.17 – 7.25 (m, 3 H), 7.77 (d, J=7.80 Hz, 1 H). HRMS 
(ESI) calcd for C25H36ClN3O5: [M+H]: 494.2422 Found: 494.2412.
4.1.8.2. 2-(benzyloxy)ethyl ((S)-3-cyclohexyl-1-(((S)-1-hydroxy-3-((S)-2-
oxopyrrolidin-3-yl)propan-2-yl)amino)-1-oxopropan-2-yl)carbamate 10b: White solid 
(yield 97%); M.p 68–69 °C; 1H NMR (400 MHz, CDCl3-d): δ ppm 0.83 – 1.04 (m, 2 H), 
1.11 – 1.24 (m, 3 H), 1.31 – 1.41 (m, 1 H), 1.51 (dd, J=8.59, 5.27 Hz, 2 H), 1.68 (d, J=9.28 
Hz, 6 H), 1.80 (d, J=8.79 Hz, 2 H), 2.02 (br. s., 1 H), 2.33 – 2.46 (m, 2 H), 3.23 – 3.34 (m, 2 
H), 3.55 – 3.61 (m, 3 H), 3.66 (s, 2 H), 3.94 – 4.05 (m, 1 H), 4.24 (s, 2 H), 4.55 (s, 2 H), 
5.59 (d, J=5.66 Hz, 1 H), 6.33 (s, 1 H), 7.28 – 7.41 (m, 5 H), 7.64 (d, J=6.44 Hz, 1 H). 
HRMS (ESI) calcd for C26H39N3O6: [M+H]: 490.2917 Found: 490.2907.
4.1.8.3. N-((S)-3-cyclohexyl-1-(((S)-1-hydroxy-3-((S)-2-oxopyrrolidin-3-yl)propan-2-
yl)amino)-1-oxopropan-2-yl)undecanamide 10c: White solid (yield 97%); M.p 78–
80 °C; 1H NMR (400 MHz, CDCl3-d): δ ppm 0.88 (t, J=6.20 Hz, 3 H), 0.96 (d, J=10.94 Hz, 
2 H), 1.09 – 1.19 (m, 3 H), 1.20 – 1.34 (m, 14 H), 1.51 (d, J=7.42 Hz, 1 H), 1.58 – 1.73 (m, 
10 H), 1.80 (d, J=10.15 Hz, 2 H), 2.03 (br. s., 1 H), 2.36 – 2.55 (m, 2 H), 3.30 – 3.41 (m, 2 
H), 3.63 (s, 3 H), 4.04 (t, J=7.00 Hz, 2 H), 4.19 – 4.28 (m, 1 H), 5.34 (d, J=7.80 Hz, 1 H), 
6.45 (s, 1 H), 7.67 (d, J=5.60 Hz, 1 H). HRMS (ESI) calcd for C27H49N3O5: [M+H]: 
496.3750 Found: 496.3745.
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4.1.9. Synthesis of aldehydes 11a–c—Compound 10 (5 mmol) was dissolved in 
anhydrous dichloromethane (50 mL) under a nitrogen atmosphere and cooled to 0°C. Dess-
Martin periodinane reagent (3.18 g, 7.5 mmol, 1.5 eq) was added to the reaction mixture 
with stirring. The ice bath was removed and the reaction mixture was stirred at room 
temperature for 3 h (monitoring by TLC indicated complete disappearance of the starting 
material). A solution of 10% aqueous sodium thiosulfate (20 mL) was added and the 
solution was stirred for another 15 minutes. The aqueous layer was removed and the organic 
layer was washed with 10% aqueous sodium thiosulfate (20 mL), followed by saturated 
aqueous sodium bicarbonate (2 × 20 mL), water (2 × 20 mL) and brine (20 mL). The organic 
layer was dried over anhydrous sodium sulfate, filtered and concentrated. The yellow residue 
was purified by flash chromatography (silica gel/methylene chloride/ethyl acetate/methanol) 
to yield aldehydes 11a–c.
4.1.9.1. 3-chlorophenethyl ((S)-3-cyclohexyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-
oxopyrrolidin-3-yl)propan-2-yl)amino)propan-2-yl)carbamate 11a: White solid (yield 
76%); M.p 45–47 °C; 1H NMR (400 MHz, CDCl3-d): δ ppm 0.86 – 1.01 (m, 2 H), 1.10 – 
1.27 (m, 2 H), 1.30 – 1.45 (m, 2 H), 1.47 – 1.58 (m, 1 H), 1.60 – 1.89 (m, 6 H), 1.92 – 2.00 
(m, 2 H), 2.01 – 2.10 (m, 1 H), 2.36 – 2.51 (m, 2 H), 2.91 (t, J=6.69 Hz, 2 H), 3.31 – 3.43 
(m, 2 H), 4.16 – 4.37 (m, 4 H), 5.25 (d, J=8.20 Hz, 1 H), 5.96 (br. s., 1 H), 7.10 (d, J=6.35 
Hz, 1 H), 7.17 – 7.25 (m, 3 H), 8.36 (d, J=5.57 Hz, 1 H), 9.49 (s, 1 H). HRMS (ESI) calcd 
for C25H34ClN3O5: [M-]: 491.2187. Found: 491.2198.
4.1.9.2. 2-(benzyloxy)ethyl ((S)-3-cyclohexyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-
oxopyrrolidin-3-yl)propan-2-yl)amino)propan-2-yl)carbamate 11b: White solid (yield 
78%); M.p 38–40 °C; 1H NMR (400 MHz, CDCl3-d): δ ppm 0.84 – 1.04 (m, 2 H), 1.11 – 
1.30 (m, 2 H), 1.39 (d, J=3.22 Hz, 1 H), 1.48 – 1.57 (m, 1 H), 1.71 (dd, J=13.57, 8.69 Hz, 6 
H), 1.78 – 1.88 (m, 2 H), 1.93 – 1.98 (m, 1 H), 2.01 – 2.09 (m, 1 H), 2.32 – 2.52 (m, 2 H), 
3.25 – 3.36 (m, 2 H), 3.67 (t, J=4.54 Hz, 4 H), 4.25 (d, J=2.93 Hz, 1 H), 4.30 – 4.39 (m, 1 
H), 4.51 – 4.62 (m, 2 H), 5.37 (d, J=8.01 Hz, 1 H), 5.99 (br s, 1 H), 7.34 (s, 5 H), 8.24 (d, 
J=4.88 Hz, 1 H), 9.49 (s, 1 H). HRMS (ESI) calcd for C26H37N3O6: [M-]: 487.2682. Found: 
487.2683.
4.1.9.3. N-((S)-3-cyclohexyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-
yl)amino) propan-2-yl)undecanamide 11c: Sticky solid (yield 71%); 1H NMR (400 MHz, 
CDCl3-d): δ ppm 0.88 (t, J=6.71 Hz, 2 H), 0.91 – 1.01 (m, 2 H), 1.07 – 1.36 (m, 16 H), 1.49 
– 1.64 (m, 4 H), 1.69 (d, J=5.71 Hz, 6 H), 1.77 – 1.90 (m, 2 H), 1.91 – 1.99 (m, 1 H), 2.02 – 
2.14 (m, 1 H), 2.27 – 2.58 (m, 3 H), 3.31 – 3.42 (m, 2 H), 3.94 – 4.12 (m, 2 H), 4.28 – 4.39 
(m, 1 H), 4.41 – 4.53 (m, 1 H), 5.20 – 5.27 (m, 1 H), 6.16 – 6.24 (m, 1 H), 8.21 – 8.28 (m, 1 
H), 9.57 (s, 1 H). HRMS (ESI) calcd for C27H47N3O5: [M-]: 493.3516. Found: 493.3518.
4.1.10. Synthesis of bisulfite adducts 12a–c—To a solution of aldehyde 11 (5 mmol) 
in dry ethyl acetate (20 mL) was added absolute ethanol (12 mL) with stirring, followed by a 
solution of sodium bisulfite (540 mg; 5 mmol) in water (5 mL). The reaction mixture was 
stirred for 3 h at 50 °C. The reaction mixture was allowed to cool to room temperature and 
then vacuum filtered. The solid was thoroughly washed with absolute ethanol and the filtrate 
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was dried over anhydrous sodium sulfate, filtered, and concentrated to yield a yellowish oil. 
The oily product was treated with ethyl ether (2 × 50 mL) to form white solid. The white 
solid was stirred with ethyl ether (30 mL) and ethyl acetate (15 mL) for 5 minutes. Careful 
removal of the solvent using a pipette yielded compounds 12a–c.
4.1.10.1. Sodium (2S)-2-((S)-2-(((3-chlorophenethoxy)carbonyl)amino)-3-
cyclohexylprop anamido)-1-hydroxy-3-((S)-2-oxopyrrolidin-3-yl)propane-1-sulfonate 
12a: White solid (yield 68%); M.p 76–78 °C; 1H NMR (400 MHz, DMSO-d6): δ ppm 0.76 
– 0.92 (m, 2 H), 1.02 – 1.17 (m, 3 H), 1.25 (d, J=13.38 Hz, 1 H), 1.40 (d, J=4.69 Hz, 2 H), 
1.51 – 1.75 (m, 6 H), 1.80 – 2.02 (m, 1 H), 2.03 – 2.23 (m, 2 H), 2.87 (d, J=3.81 Hz, 2 H), 
2.99 – 3.08 (m, 1 H), 3.08 – 3.20 (m, 1 H), 3.69 – 3.87 (m, 2 H), 3.88 – 4.04 (m, 1 H), 4.14 
(d, J=6.54 Hz, 3 H), 5.43 – 5.48 (m, 1 H), 7.19 – 7.38 (m, 4 H), 7.47 (br s, 1 H), 7.55 (dd, 
J=14.94, 9.08 Hz, 2 H). HRMS (ESI) calcd for C25H35ClN3O8SNa: [M-]: 595.1731. Found: 
595.1733.
4.1.10.2. Sodium (8S,11S)-8-(cyclohexylmethyl)-12-hydroxy-6,9-dioxo-11-(((S)-2-oxo 
pyrrolidin-3-yl)methyl)-1-phenyl-2,5-dioxa-7,10-diazadodecane-12-sulfonate 
12b: White solid (yield 73%); M.p 47–50 °C; 1H NMR (400 MHz, DMSO-d6): δ ppm 0.78 
– 0.94 (m, 2 H), 1.01 – 1.22 (m, 4 H), 1.32 (br s, 1 H), 1.39 – 1.51 (m, 2 H), 1.53 – 1.72 (m, 
6 H), 1.86 – 1.94 (m, 1 H), 2.00 – 2.34 (m, 2 H), 2.99 – 3.18 (m, 2 H), 3.60 (d, J=3.71 Hz, 4 
H), 3.75 (q, J=7.13 Hz, 1 H), 4.00 – 4.22 (m, 2 H), 4.50 (s, 2 H), 7.25 – 7.38 (m, 5 H), 7.43 
(d, J=7.13 Hz, 1 H), 7.54 (br s, 1 H), 7.64 (br s, 1 H), 8.47 (d, J=7.03 Hz, 1 H). HRMS (ESI) 
calcd for C26H38N3O9SNa: [M-]: 591.2226. Found: 591.2227.
4.1.10.3. Sodium (2S)-2-((S)-3-cyclohexyl-2-undecanamidopropanamido)-1-hydroxy-3-
((S)-2-oxopyrrolidin-3-yl)propane-1-sulfonate 12c: White solid (yield 67%); M.p 53–
55 °C; 1H NMR (400 MHz, DMSO-d6): δ ppm 0.86 (t, J=6.13 Hz, 2 H), 1.07 – 1.14 (m, 2 
H), 1.25 (br s, 16 H), 1.39 (d, J=19.72 Hz, 2 H), 1.52 (br s, 5 H), 1.62 (br. s., 6 H), 1.87 – 
2.02 (m, 2 H), 2.12 (d, J=7.23 Hz, 2 H), 3.01 – 3.20 (m, 2 H), 3.82 – 4.00 (m, 2 H), 4.05 (br. 
s., 1 H), 4.17 – 4.29 (m, 1 H), 5.29 – 5.36 (m, 1 H), 5.73 – 5.78 (m, 1 H), 7.14 – 7.19 (m, 1 
H), 7.47 (d, J=9.15 Hz, 1 H), 7.58 (s, 1 H). HRMS (ESI) calcd for C27H48N3O7SNa: [M-]: 
597.3060. Found: 597.3063.
4.2. X-ray crystallographic studies. Crystallization and data collection
Purified norovirus 3CL Protease (NV 3CLpro) in 100 mM NaCl, 20 mM Tris pH 8.0 (11 
mg/mL) was used for preparation of the inhibitor complexes. Stock solutions (100 mM) of 
each inhibitor were prepared in DMSO and added to NV 3CLpro by mixing 7 μL of the 
inhibitor (3 mM) with 243 μL (0.5 mM) of NV 3CLpro and incubating on ice for 1 hour. All 
crystallization experiments were conducted Compact Jr. (Rigaku Reagents) sitting drop 
vapor diffusion plates at 20 °C using equal volumes of protein and crystallization solution 
equilibrated against 75 μL of the latter. Hexagonal NV 3CLpro:7l (h) and orthorhombic 
crystals NV 3CLpro:7l (o) were obtained for the NV 3CLpro:7l complex in 2–3 days from 
the Index HT screen (Hampton Research) condition G5 (25% (w/v) PEG 3350, 100 mM Tris 
pH 8.5, 200 mM lithium sulfate) and Wizard 3–4 screen (Rigaku Reagents) condition A10 
(20% (w/v) PEG 3350, 200 mM sodium thiocyanate) respectively. Crystals of the complex 
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with inhibitor 7m (NV 3CLpro:7m) were also obtained from the Index HT G5 condition. 
Samples were transferred to a fresh drop composed of 80% crystallization solution and 20% 
(v/v) PEG 200 and stored in liquid nitrogen. X-ray diffraction data were collected at the 
Advanced Photon Source beamline 17-ID using a Dectris Pilatus 6M pixel array detector.
4.3. Structure Solution and Refinement
Intensities were integrated using XDS [34,35] via Autoproc [36] and the Laue class analysis 
and data scaling were performed with Aimless [37]. Structure solution was conducted by 
molecular replacement with Phaser [38] using a previously determined structure of inhibitor 
bound to NV 3CLpro (PDB: 3UR9) [32] as the search model. Each crystal form contained 
two molecules in the asymmetric unit. Structure refinement and manual model building were 
conducted with Phenix [39] and Coot [40], respectively. Disordered side chains were 
truncated to the point for which electron density could be observed. Structure validation was 
conducted with Molprobity [41] and figures were prepared using the CCP4MG package 
[42]. Structure superposition was conducted with GESAMT [43].
4.4. FRET protease assays
The FRET protease assay was performed by preparing stock solutions of the substrate 
(Edans-DFHLQ/GP-Dabcyl) and inhibitor in DMSO and diluting into assay buffer which 
was comprised of 20mM HEPES buffer, pH 8, containing NaCl (200 mM), 0.4 mM EDTA, 
glycerol (60%), and 6 mM dithiothreitol (DTT). The protease was mixed with serial 
dilutions of each compound or with DMSO in 25 μL of assay buffer and incubated at 37°C 
for 30 min, followed by the addition of 25 μL of assay buffer containing substrate. 
Fluorescence readings were obtained using an excitation wavelength of 360 nm and an 
emission wavelength of 460 nm on a fluorescence microplate reader (FLx800; Biotec, 
Winoosk, VT) 1 h following the addition of substrate. Relative fluorescence units (RFU) 
were determined by subtracting background values (substrate-containing well without 
protease) from the raw fluorescence values, as described previously [25,31–32]. The dose-
dependent FRET inhibition curves were fitted with a variable slope by using GraphPad 
Prism software (GraphPad, La Jolla, CA) in order to determine the IC50 values of the 
inhibitors.
4.5. Cell-based inhibition assays
The effects of each inhibitor on virus replication were examined in the NV replicon 
harboring cells (HG23 cells) [32]. Briefly, confluent and semi-confluent cells were 
incubated with medium containing DMSO (<0.1%) or each compound (up to 100 μM) for 
48 h. After the incubation, total RNA was extracted and viral genome was quantitated with 
real-time quantitative RT-PCR (qRT-PCR). The EC50 values were determined by 
GraphPadPrism software [32].
4.6. Nonspecific cytotoxic effects
The cytotoxic dose for 50% cell death (CC50) for each compound was determined for HG23 
cells used in this study. Confluent cells grown in 96-well plates were treated with various 
concentrations (1 to 100 μM) of each compound for 72 h. Cell cytotoxicity was measured by 
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a CytoTox 96 nonradioactive cytotoxicity assay kit (Promega, Madison, WI) and crystal 
violet staining. The in vitro therapeutic index was calculated by dividing the CC50 by the 
EC50.
4.7. Accession Codes
Coordinates and structure factors were deposited to the Worldwide Protein Data Bank 
(wwPDB) with the accession codes: NV 3CLpro-7l (h) (5T6D), NV 3CLpro-7l (o) (5T6F), 
and NV 3CLpro-7m (5T6G).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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General structure of inhibitor (I)
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Fo-Fc omit map of inhibitor 7l (green mesh) contoured at 3σ for (A) NV 3CLpro:7l 
(hexagonal) and B) NV 3CLpro:7l (orthorhombic).
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Electrostatic surface representation of NV 3CLpro showing the aryl ring region of inhibitor 
7l positioned in the hydrophobic S4 pocket.
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Hydrogen bond interactions (dashed lines) for (A) NV 3CLpro:7l (hexagonal) and B) NV 
3CLpro:7l (orthorhombic).
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Surface representation of NV 3CLpro:7l (hexagonal) with neighboring residues colored 
yellow (nonpolar), cyan (polar), and white (weakly polar). A) View of the inhibitor in the 
S1/S2 pocket and B) the S4 pocket.
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Fo-Fc omit map of inhibitor 7m (green mesh) contoured at 3σ.
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Surface representation of NV 3CLpro:7m with neighboring residues colored yellow 
(nonpolar), cyan (polar), and white (weakly polar). A) View of the inhibitor in the S1/S2 
pocket and B) the S4 pocket.
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Superposition of inhibitor 7l (gray) and 7m (coral) which adopt similar binding modes in the 
NV 3CLpro active site
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Hydrogen bond interactions (dashed lines) for NV 3CLpro:7m.
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Electrostatic surface representation of NV 3CLpro showing the aliphatic chain of inhibitor 
7m positioned in a hydrophobic S4 pocket.
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Synthesis of Inhibitors 6a–m and 7a–m
aEDCI/HOBt/DIEA/DMF then 8; b4M HCl in dioxane/2h; cRSO2Cl/TEA/DCM/35°C; d2M 
LiBH4/THF/CH3OH;eDess-Martin periodinane/DCM; fC2H5OH/EtOAc/NaHSO3
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Synthesis of Inhibitors 11a–c and 12a–c
aROCOCl/TEA/DCM/ reflux 3 hrs; b2M LiBH4/THF/CH3OH;cDess-Martin periodinane/
DCM; dC2H5OH/EtOAc/NaHSO3
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Table 1
Activity of compounds 6a–m and 7a–m against NV 3CL protease and replicon harboring cells.
Compound R IC50 (μM) EC50 (μM) CC50 (μM)
6a
C6H5
8.5 9.5 > 100
7a 13.5 12.3 > 100
6b
(C6H5) CH2
4.5 4.1 > 100
7b 4.3 4.3 > 100
6c
(C6H5) CH2CH2
1.8 0.7 > 100
7c 2.1 0.8 > 100
6d
p-F (C6H4)
4.8 2 > 100
7d 6.2 2.1 > 100
6e
m-Cl (C6H4)
5.5 2.3 > 100
7e 5.7 1.9 > 100
6f
p-Cl (C6H4)
5.8 3.5 > 100
7f 5.1 7.2 > 100
6g
p-Cl (C6H4) CH2
1.8 2.4 > 100
7g 1.2 2.2 > 100
6h
m-Cl (C6H4) CH2CH2
2.3 1.1 > 100
7h 1.9 0.8 > 100
6i
2-Thiophene
10.4 8.5 > 100
7i 8.5 8.1 > 100
6j
Biphenyl-4-
1.3 1.3 > 100
7j 1.1 1.2 > 100
6k
2-Phthalimidoethane
2.5 2.3 > 100
7k 2.6 2.1 > 100
6l
p-CH3O(C6H4)O(CH2)3
1.8 0.2 > 100




7m 1.1 0.2 35.4
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Table 2
Activity of compounds 11a–c and 12a–c against NV 3CL protease and replicon harboring cells




12a 0.5 0.1 46.7
11b
(C6H5)CH2O(CH2)2
2.1 0.2 > 100




12c 0.4 0.2 34.5
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Table 3
Crystallographic Data for NV 3CL Protease-Inhibitor Structures
NV 3CLpro:7l (h) NV 3CLpro:7l (o) NV 3CLPro:7m
Data Collection
 Unit-cell parameters (Å, °) a=b=59.53, c=356.80 a=37.51, b=64.80, c=125.37 a=b=59.58, c=357.70
 Space group P6122 P212121 P6122
 Resolution (Å)1 49.53–2.10 (2.16–2.10) 45.05–1.90 (1.94–1.90) 49.57–2.45 (2.55–2.45)
 Wavelength (Å) 1.0000 1.0000 1.0000
 Temperature (K) 100 100 100
 Observed reflections 434,656 158,261 276,664
 Unique reflections 23,382 24,911 15,076
 <I/σ(I)>1 13.4 (1.9) 13.7 (2.1) 13.2 (1.9)
 Completeness (%)1 100 (99.9) 99.9 (100) 100 (100)
 Multiplicity1 18.6 (18.9) 6.4 (5.8) 18.4 (19.5)
 Rmerge (%)1, 2 20.7 (186.3) 9.9 (92.6) 25.1 (197.3)
 Rmeas (%)1, 4 21.3 (191.5) 10.7 (101.8) 25.8 (202.6)
 Rpim (%)1, 4 4.9 (43.8) 4.2 (41.6) 6.0 (45.5)
 CC1/2 1, 5 0.998 (0.897) 0.999 (0.834) 0.997 (0.714)
Refinement
 Resolution (Å) 1 47.30–2.10 35.94–1.90 49.57–2.45
 Reflections (working/test)1 22,094/1,115 23,626/1,210 14,228/727
 Rfactor / Rfree (%)1,3 19.3/24.3 19.4/24.9 18.8/26.1
 No. of atoms (Protein/Ligand/Water) 2,440/74/108 2,400/63/104 2,473/63/74
Model Quality
R.m.s deviations
 Bond lengths (Å) 0.010 0.010 0.008
 Bond angles (°) 1.040 1.031 0.924
Average B-factor (Å2)
 All Atoms 32.6 35.4 38.1
 Protein 32.3 35.3 38.1
 Ligand 35.5 38.3 36.7
 Water 38.2 37.2 39.7
 Coordinate error(maximum likelihood) (Å) 0.23 0.22 0.28
Ramachandran Plot
 Most favored (%) 96.9 96.0 94.9
 Additionally allowed (%) 3.1 3.7 4.8
1
Values in parenthesis are for the highest resolution shell.
2
Rmerge = ΣhklΣi |Ii(hkl) - <I(hkl)>| / ΣhklΣi Ii(hkl), where Ii(hkl) is the intensity measured for the ith reflection and <I(hkl)> is the average 
intensity of all reflections with indices hkl.
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3
Rfactor = Σhkl ||Fobs (hkl) | - |Fcalc (hkl) || / Σhkl |Fobs (hkl)|; Rfree is calculated in an identical manner using 5% of randomly selected 
reflections that were not included in the refinement.
4
Rmeas = redundancy-independent (multiplicity-weighted) Rmerge[37, 44]. Rpim = precision-indicating (multiplicity-weighted) Rmerge[45, 46].
5
CC1/2 is the correlation coefficient of the mean intensities between two random half-sets of data [47, 48].
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